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Sphingolipids are diverse family of molecules found in all eukaryotes and some 
prokaryotes. They modulate critical functions related to cell survival, apoptosis, 
migration and membrane structures. As sphingolipids and their biosynthetic pathways are 
highly complex, studies in sphingolipid metabolism have been challenging. This 
dissertation addresses this challenge by the novel application of bioinformatics analysis 
to investigate sphingolipid and glycosphingolipid alterations at the system, as well as 
molecular levels.  
As part of this thesis, updated pathway maps were prepared based on recent 
reports to visualize differences in gene expression and metabolites in the different 
branches of sphingolipid biosynthesis. Supporting Perl scripts were written to extract and 
format gene expression datasets for pathway visualization.  
Cancer gene expression datasets were examined for sphingolipid gene expression 
differences using the pathway maps and compared to metabolites that were either 
reported or analyzed by mass spectrometry analysis conducted during this study.  
Comparison of 9 gene expression datasets and corresponding sphingolipid alterations 
identified a 72.8% correlation between transcript and metabolite pattern at a significance 
p < 0.0001using the Fisher’s exact test. This study also discovered hydroxyl 
sphingolipids (phyto-sphingolipids) and short chain ceramides in MCF-7 and MDA-MB-
231 cells respectively that were initially predicted by a gene expression pathway diagram.  
The next study focuses on the discovery of the transcript that encodes the human 
3-Ketosohinganine reductase (3KSR) which was not identified during the preparation of 
the pathway map. By blast comparison to the yeast enzyme sequence, Follicular 
 xviii 
lymphoma type 1 (FVT1) was identified as the human homolog of 3KSR. After over 
expressing FVT1 in Hela cells and E.coli, its 3KSR activity was verified by an invitro 
enzyme activity assay. In Hela cells we have further discovered that the absence of 
FOXC1, a putative transcription regulator of FVT1 results in lower 3KSR activity and the 
accumulation of intermediate sphingolipids.  
 One of the critical factors influencing de novo sphingolipid biosynthesis is the 
expression of serine palmitoyltransferase (SPTLC1 and SPTLC2 subunits) and its role 
has been widely studied using a Chinese hamster ovary cells (LY-B) that lack the 
enzyme. Because the molecular abnormality of LY-B cells in the cells was unknown, we 
cloned the SPTLC1 transcript and discovered a point mutation. Homology modeling of 
the mutant protein suggested that the substitution would cause the protein to misfold and 
degrade. The use of chemical chaperones, DMSO and glycerol resulted in the partial 
stabilization of the SPT peptide but no significant SPT activity was determined. 
 These studies demonstrate the application of bioinformatics to investigate 
different molecular aspects of the sphingolipid biosynthesis.  
  








1.1 Sphingolipids and their structural diversity 
Sphingolipids are diverse family of lipids found in most eukaryotes and some 
prokaryotes [1]. They play important roles in cellular processes such as proliferation [2], 
migration, apoptosis [3, 4] and membrane structure. Abnormalities in their biosynthesis 
have been linked to neurodegenerative diseases [5, 6], lipid storage disorders [7] and 
carcinogenesis [8, 9].  Structurally, they are comprised of a sphingoid base (Fig 1), that 
may be N-acylated with a fatty acid of chain lengths C14-C30 (Fig 1.1). The 1-hydroxy 
(1-OH) position of sphingolipids can be modified by a phosphocholine, phosphate or 
complex carbohydrate headgroup (Fig 1). Besides sphinganine and sphingosine 
(sphingoid bases without and with a 4,5 unsaturation, respectively), other detected 
variations in sphingoid bases include 4-hydroxylation, iso and ante-iso methylation [10]. 
Recent reports have shown that shorter sphingoid bases can be produced by the 
condensation of palmitoyl-CoA with alanine and glycine [11] or the condensation of 





Fig 1.1. Illustration of backbone sphingolipid structure and putative headgroup 
modifications. The figure displays variations in sphingoid base and some of the possible 
headgroup modifications. Variations of the sphingoid base include Sphingosine, d18:1 
(also called sphingenine) (shown), Sphinganine, d18:0 (dihydrosphingosine), 4- 
Hydroxysphinganine, t18:0 (phytosphingosine), Sphingadiene, d18:2 (e.g., 4-trans,14-
cis) and others. Modifications in fatty acids include Amide-linked fatty acids (C14 to 30)/ 
mostly saturated (or mono-unsaturated)/sometimes with an - or -hydroxyl group 
(abbreviation for compound shown: d18:1/16:0).  The 1-position of the sphingoid base 
can be modified by moieties including phosphocholine sulfatides or glycans. 
Representative combinations of sugar residues in ganglioside are also displayed. This 
figure is adapted from a previous article [1] 
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1.2 De novo biosynthesis of ceramide and less complex 
glycosphingolipids 
 
De novo biosynthesis of backbone sphingolipids [1] begins with the condensation 
of L-serine and palmitoyl-CoA by serine palmitoyltransferase (SPT) (Fig 1.1 A) to 
produce 3-ketosphinganine (3-KSa) that is reduced to sphinganine (Sa) by 3-
ketosphinganine reductase (3KSR).  Sphinganine can be N-acylated by fatty acid specific 
(dihydro) ceramide synthases (CerS1-6) (Fig 1.1 A) [14-18] to produce dihydroceramides 
with variable chain length fatty acids. A 4,5-double bond can then be introduced by 
dihydroceramide desaturase (DES1 and DES2) to generate different ceramide subspecies. 
In addition to 4,5 desaturation, DES2 also catalyzes  a 4-hydroxylation reaction which is 
responsible for the synthesis of phytoceramide [19].  Glucosylceramide (GlcCer) and 
galactosylceramide (GalCer) are produced by the addition of glucose and galactose 
residues respectively, at the 1-hydroxy position of ceramide (Fig 1.1 A), whereas 
sphingomyelin and ceramide 1-phosphate are formed by the attachment of 
phosphatidylcholine and phosphate headgroups respectively.  
An alternate approach to generate ceramides is by the turnover of complex 
sphingolipids [20], such as sphingomyelin (SM), GlcCer and GalCer by degradative 
enzymes.  Ceramides can also be catabolized to sphingosine and then to sphingosine 1-
phosphate (So 1-P) by acid ceramidase (ASAH 1) and sphingosine kinase (SPHK1, 
SPHK2), respectively, and So 1-P is degraded as ethanolamine phosphate and 






Figure 1.2. Biosynthesis of backbone sphingolipids and initial steps of complex 
sphingolipid metabolism. The illustration depicts early step of sphingolipid backbone 
formation and conversion to different branches of complex sphingolipid A) Backbone 
synthesis begins with the condensation of serine and palmitoyl-CoA by Serine 
palmitoyltransferase (SPT) to produce 3-Ketosphinganine, sphinganine, 
dihydroceramide, ceramide , ceramide 1-phosphate, glucosylceramide, 
galactosylceramide and sphingomyelin. Fatty acid specific ceramide synthases attaches 
N-acyl chain of different chain length to the sphingoid base backbone. Ceramides are 
degraded by conversion to sphingosine and then to sphingosine 1-phosphate.  B) 
Metabolism of glucosylceramide to different branches of glycosphingolipids; 
ganglioside, isogloboseries, globoseries, neo-lacto-series and lacto-series begins with the 
attachment of different sugar groups. This figure is adapted from a previous article [1] 
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1.3 Biosynthesis of more complex glycosphingolipids 
 
Synthesis of glycosphingolipid (GSL) species is initiated by the attachment of 
charged and uncharged sugar residues to GlcCer and GalCer (Fig 1.2 B) in a 
combinatorial fashion to produce acidic (charged) and neutral GSLs. While neutral GSL 
contain uncharged sugar residues such as glucose (Glc), galactose (Gal), N-
acetylglucoseamine (GlucNAc) , N-acetylgalactoseamine and Fucose (Fuc) sugars, acidic 
GSL contain charged sugar residues such as sialic acid and glucuronic acid or headgroups 
such as phosphate and sulphate in addition to neutral sugar residues. 
Acidic and neutral GSL are further classified based on the combination of a few 
initial sugar residues and the presence and absence of charged sugar residues,  (Fig 1.2 B) 
such as ganglioside (Galβ1–3GalNacβ1–4Galβ1–4Glcβ1–1 Cer), Lactoseries (Galβ1–
3GlcNacβ1–3Galβ1–4Glcβ1–1 Cer), Neolacto-series (Galβ1–4GlcNacβ1–3Galβ1–
4Glcβ1–1 Cer), Globo-series (GalNacβ1–3Galα1–4Galβ1–4Glcβ1–1 Cer) and Isoglobo-
series (GalNacβ1–3Galα1–3Galβ1–4Glcβ1–1 Cer).  While most of the ganglioside and 
globoseries headgroups are specific to GSL, glycans belonging to other classes such as 
lacto-series and neo-lacto series are shared between glycolipids and glycoproteins.  The 
biosynthesis of two abundant branches of GSL is described below. 
 
 1.3.1 Ganglioside biosynthesis 
Stepwise addition of sialic acids to the carbohydrate headgroup of 
lactosylceramide(LacCer) results in the formation of simple gangliosides, i.e. monosialyl 
ganglioside (GM3) , disialyl ganglioside (GD3) and trisialyl ganglioside (GT3) (Fig 1.3 
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A). These species are further metabolized to more complex gangliosides by the 
attachment of charged and uncharged sugar residues for example GM3 is the precursor to 
GM2, GM1a, GD1a and GT1a, GD3 is converted to GD2, GD1b, GT1b and GQ1b, and 
GT3 is metabolized to GT2, GT1c, GQ1c and GP1c.  In contrast, direct linkage of non-
sialic acid residues to LacCer results in the formation of asialo-gangliosides species, GA2 
and GA1.  GSL formed using GM3, GD3 and GT3 as precursors are referred as A-, B- 
and C-series ganglioside respectively, and are usually indicated by the suffix „a‟, „b‟ and 
„c‟ attached with their name (Fig 1.3 A).  
 
1.3.2 Globoseries biosynthesis 
  
Neutral GSL are formed by the metabolism of LacCer (Fig. 1.3 B) to 
ceramidetrihexoside (Gb3) that is converted to globoside (Gb4), which serves as the 
precursor to the formation of Forssman and para-forssman antigen), stage specific 
embryonic antigen-3 (Gb5, which is the precursor for Globo-H and Type IV A and B 
antigens) and stage specific embryonic antigen-4 (monosialyl-Gb5, which can be sialated 






Figure 1.3 Biosynthesis of gangliosides and globoseries glycosphingolipids 
Ganglioside  
biosynthesis illustrated in (A) results in the formation of asialo-ganglioside (GA2 and 
Ga1), monosialyl-ganglioside( GM3, GM2, GM1a and GD1a), disialyl-ganglioside 
(GD3, GD2, GD1b and Gt1b) and trisialyl-ganglioside (GT3, GT2, GT1c and GQ1c). 
Structural isomers belonging to A, B or C series are indicated with a suffix 'a', 'b' and 'c'. 
B) shows the metabolism of LacCer to globoseries glycolipids; ceramidetrihexoside 
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(Gb3), globoside (Gb4), Forssman and para-forssman antigen, stage specific embryonic 
antigen-3 (SSEA-3), Globo-H  antigen, stage specific embryonic antigen-4 (SSEA-4) and 
disialyl-Gb5. The layout of the modified pathway maps is based on KEGG (Kyoto 
Encyclopedia of Genes and Genomes, map00603 and map00604) pathway diagram, 
which were prepared using a GenMapp v2.1. The objects with different shapes and colors 
represent different sugar residues as indicated in the figure legend. Glucose (Glc), N-acyl 
glucose amine (GlcNAc), Galactose (Gal), N-acyl galactose amine (GalNAc), Fucose 










































1.4 Biological functions of sphingolipids 
 
1.4.1 Membrane structure 
Sphingolipids are components of lipids rafts [21] (detergent insoluble glycolipids 
enriched complexes) and glycosynapses in the plasma membrane [22]. Lipid rafts tend to 
cluster other important cell signaling proteins  and G-protein coupled receptors including 
CD95/FAS [23, 24], EGFR [25] and nitric oxide synthase [26, 27]. Therefore changes in 
membrane lipid composition of sphingolipids and glycolipids have been noted to cause  
alterations of Serotonin (5-hydroxytryptamine) receptor activity [28] and bacterial 
adhesion to cell membrane (Helicobacter pylori) [29].  Another form of membrane 
micro-domain shown to contain sphingolipid molecules are “glycosynapses”, wherein 
GSL accumulate with their binding proteins such as tetraspanins, integrins [30], growth 
factor receptors [31] and signaling molecules [32]. Through these interactions [33] GSL 




GSL are largely localized to the outer leaflet of the plasma membrane and the 
lumens of the Golgi and endosomes, where they interact with receptors, glycoconjugates 
and extracellular proteins of neighboring cells through direct carbohydrate-carbohydrate 
interaction and carbohydrate-protein interactions [34].Their interactions with selectins 
[35], siglecs [36] and galectins [37], facilitate cell recognition and adhesion. One 
example is the adhesion and invasion of macrophages into inflamed renal tissue is 
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dependent upon the interaction between sulfatides and L-selectins [35]. In contrast, 
interaction of GM3 with CD9 tetraspanin inhibits haptotactic motility [38].  GSL have the 
capability to bind molecules on the same cell surface, for example GM3  binds and 
modulates epidermal growth factor receptor signaling  (EGFR) through carbohydrate-
carbohydrate interaction [39, 40].Glycan headgroups of GSLs are also recognized by 
viruses, bacteria and pathogens, and aid in binding and invasion of the host cells [41, 42].   
 
1.4.3 Cell signaling  
Backbone sphingolipids such as sphingosine, ceramide, sphingosine 1-phosphate 
and ceramide 1-phosphate serve as important  second messenger molecules [43]. 
Sphingosine (So) and its N-methyl derivatives have been shown to inhibit protein kinase 
C (PKC) [19, 44, 45] and induce cell death. Ceramide, like sphingosine also interact with 
various members of the PKC family to initiate cell signaling through Bad/Bax, ERK and 
prostate apoptosis response-4 (PAR4) [46, 47] [48]. It induces apoptosis by promoting 
the phosphorylation and Golgi translocation of PKCα, PKCδ and PKCε [49-51], while it 
interacts with PKCβ2 and inhibits its juxtanuclear translocation [52]. Direct binding of 
ceramide to  PKCξ was shown to cause the formation of a pro-apoptotic complex,  PAR4 
and induce cell death [48].  Ceramide also binds and activates protein phosphatase 2A 
(PP2A) and protein phosphatase 1 (PP1), which induces apoptosis by activating pro-
apoptotic factors BAD and BAX [46, 47] and inactivating anti-apoptotic factors, bcl-2 
and bcl-XL [53, 54]. The interaction of ceramide with cathepsin D causes caspase 
independent apoptosis [55].  
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In contrast, sphingoid base 1-phosphates (Sa1P and So1P) stimulate cell motility 
and proliferation through the activation of platelet-derived growth factor (PDGF) 
receptor  [56] and the sphingosine 1-phosphate receptor family (S1P receptor, previously 
known as EDG receptors) [57].  S1P was shown to block apoptosis induced by ceramide, 
through the inhibition of caspase and SAPK/JNK activation, or by stimulating ERK 
pathway [58]. It has been proposed that the opposing effects of ceramide and So1P  
resulting in apoptosis and cell proliferation respectively, may function as a “switch” that 
can “dial” between growth, senescence and death depending on which combination is 
produced [59].  
GSLs are involved in cell signaling via interaction with various tyrosine kinase 
receptors and cell adhesion molecules. GM3 caused complete inhibition of fibroblast 
growth factor receptor (FGFR) signaling  and epidermal growth factor receptor (EGFR) 
signaling by blocking tyrosine phosphorylation in cells BHK [31, 60]. In contrast platelet 
derived growth factor receptor (PDGFR) signaling was inhibited by GD1a, GD1b, GT1b 
and GM1 [61, 62].   
Another signaling mechanism involving GM3 is through the activation of c-Src, 
Rho and focal adhesion kinase (FAK) [63] in glycosphingolipid enriched microdomains 
(GEM). The binding of B16 cells expressing GM3 to Gg3 coated dishes enhanced 
tyrosine phosphorylation of FAK and c–Src [32], resulting in higher loading of GTP in 
Rho and Ras, resulting in their activation. Interaction of GM3 was also noted with the 
CD4 –LCK protein complex [64].  
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As sphingolipids play critical roles in wide range of cell processes, their 
biosynthesis is highly regulated [65, 66]. However, an altered composition of these 
compounds has been found in a number of disorders, including neurodegenerative 
diseases [5, 6], lipid storage disorders [7] and carcinogenesis [8, 9]. The abnormal 
changes in sphingolipids have been linked to either their incomplete breakdown 
(degradation) caused by defective enzymes [7] or due to changes in gene expression and 
enzyme activity [8, 9]. 
 
1.5 Abnormal sphingolipid metabolism in cancer 
 
Malignant transformation of cells is accompanied by aberrant changes in 
sphingolipid metabolites [34]. These were initially characterized as tumor antigens using 
immunological approaches, but later studies showed that they were glycosphingolipids 
(GSL). It is suggested that the abnormal composition of GSL‟s was caused by either the 
suppression of a downstream enzyme, also termed as „blocked synthesis‟, or due to the 
induction of precursor enzyme, known as „neosynthesis‟ [34].   Some of the alterations in 









Table 1.1 Comparison of sphingolipid alteration in tumors and cell lines. 
Cancer type Subtype comparison Elevated Depleted 
Glioma Astrocytoma 
Vs Normal brain 
GM3 and GD3  [67, 68] GD1a, GD1b, GT1b and 
GQ1b [67, 68] 
 Gliosarcoma 
Vs Normal brain 
GM3, GD2, GT3, 3‟-isoLM1 
and GD3 [69] 
GM1a, GM1b, GD1a, 




GD3 [70, 71], 9-O-acetylGD3, 
de-N-acetylGD3, O-acetyl 
GM2, O-actylGD2  and sialyl-
Lea [72-74] 
 
Ovarian  Serous  
Vs normal ovary 
 Gb1, Gb2, Gb3, and 
sulfatide[75, 76] 
 
 Mucinous  
Vs normal ovary 
Gb1, Gb2, Gb3, Lewis A , 
Lewis B and sulfatide [75, 76] 
 
Prostate Metastatic  
Vs Normal 
 Gb1, Gb2, Gb3 and GD2 
[77] 
 PC3  
 Vs PREC 
GT1b, GD1b, GD1a and GM2.  
Breast Invasive ductal 
carcinoma (tissue) 
Vs normal 
GM3, GD3, N- and O-acetyl 
GD3, and GT3  [78],  SSEA-3 
and Globo-H [79, 80] 
 
 Invasive ductal 
carcinoma (serum) 
Vs normal 
GD1b, GT1b and GQ1b [81]  
 MCF7       
Vs  MDA-MB-231 
Gb4, SSEA3, Globo H [82] GM3, GM2 and GD1a 
[82] 
 
Table 1.1 Comparison of sphingolipid alteration in tumors and cell lines. The table 
depicts the differences in sphingolipid metabolites from published literature of glioma, 
melanoma, ovarian, prostate and breast tumors or cell lines. These studies quantified 
differences in sphingolipid species were quantified using analytical techniques such as 
thin layer chromatography (TLC), TLC immunostaining, high performance liquid 
chromatography or mass spectrometry. Calculated results were used to determine 
increase (elevated) or decrease (depleted) in metabolites amounts, while quantitative 
differences in TLC images were determined by densitometry analysis using the Flurchem 
5500 (Alpha Innotech). 
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The Mechanisms used by sphingolipids to influence cancer processes are 
discussed in the section below.   
 
1.5.1 Backbone sphingolipids 
Sphingolipid backbone species participate in a number of cancer cell processes 
such as cell signaling, proliferation, motility and the induction of apoptosis.  Sphingosine 
inhibits classical PKC and induces cell death [83]. Sphingosine and dimethyl sphingosine 
have been implicated in promoting sphingosine dependent kinase 1 (SDK1) dependent 
phosphorylation of 14-3-3 that prevents its dimerization and inactivation of proapoptotic 
factors, BAD and BAX [84]. 
Ceramide, like sphingosine, interacts with various members of the PKC family to 
initiate cell signaling through Bad/Bax, ERK and prostate apoptosis response-4 (PAR4) 
[46, 47] [48]. It binds and activates protein phosphatase 2A (PP2A) and protein 
phosphatase 1 (PP1 ), which induces apoptosis by activating pro-apoptotic factors BAD 
and BAX [46, 47] and inactivating anti-apoptotic factors BCL-2 and BCL-XL [53, 54], 
while the interaction of ceramide with cathepsin D results in caspase independent 
apoptosis [55]. In addition,  chemotherapeutic agents [85-87] induce apoptosis by 
stimulating the production of ceramides through the turnover of sphingomyelin or 
induction of de novo biosysnthesis. Recently, induction of ceramides by tamoxifen was 
shown to induce autophagy [88], a critical pathway for the degradation and turnover of 
cellular organelles and proteins, and an important mechanism for non-apoptotic 
programmed cell death [89]. In addition a study performed in our lab has revealed that 
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generation of dihydroceramide by the inhibition of DES by fenretnide caused 
dihydroceramide mediated autophagy [90].   
S1P plays a critical role in the process of angiogenesis [91] and the formation of 
blood vessels [92],  through activation of S1P1 receptor.  This function is critical for 
tumor angiogenesis and vascularization [93], and was suppressed by the siRNA mediated 
silencing of S1P1 receptor [94] . In addition, a recent study has demonstrated that a 
monoclonal antibody specific against S1P, arrested tumor angiogenesis and 
vascularization by inhibiting proangiogenic factors, IL-8, VEGF and bFGF [95].  S1P not 
only promote cell proliferation, but also blocks ceramide induced apoptosis by the 
inhibition of  caspase and SAPK/JNK pathways and the activation of ERK pathway [58]. 




Gangliosides play critical roles in both cell adhesion and signaling. GM3 binds 
and inhibits epidermal growth factor receptor (EGFR) signaling by inhibiting its 
phosphorylation, which results in stimulated phosphorilation of EGF receptor and growth 
inhibition by cell cycle arrest [60]. In contrast, reduction in GM3 levels leads to higher 
motility and invasiveness of YST-1 cells, which is reversible by the addition of 
exogenous GM3 [96]. In addition GM3 has been shown to inhibit FGFR signaling [167]. 
It also binds a number of extracellular proteins in the glycosynapse such as cSrc, RhoA 
and Csk. GM3 dependent activation of cSrc resulted in the induced differentiation of 
neurobalstoma cells, Neuro-2a [97], through the activation of MAPK signaling pathway 
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and the inhibition of Csk, an inhibitor of cSrc. The prophylactic treatment with anti-GM3 
vaccine caused substantial reduction in tumor metastasis in B16 mouse model by eliciting 
the production of anti-GM3 IgG [98]. It was later shown that it elicited its effect through 
the through CD8
+ 
T cells [99].  
 GD3 is another important tumor associated ganglioside that has been detected in 
many tumors including melanoma [100-103], neuroblastoma [104-107] and lymphoma 
[108, 109]. In melanoma, high quantities of GD3 promotes enhanced cell proliferation 
and invasion through the phosphorylation of paxillin and P130CAS [110], while the 
suppression of paxillin and P130CAS inhibited GD3 mediated invasion and proliferation. 
Increase in ceramide amounts also augments GD3 level that triggers apoptosis through 
mitochondrial permeability transition [111-114], cytochrome-c release [115, 116] and 
caspase activation [108, 117, 118]. The treatment of cancer cells with fenretnide results in 
GD3 dependent formation of reactive oxygen species that triggers caspase-3 dependent 




Sulfatides are essential sulfated glycolipids that are mainly found on the cell 
surface where they interact with extracellular membrane proteins such as laminin [121, 
122], L-selectins [35], P-selectins [123, 124] and thrombospondin [125, 126]. These 
interactions facilitate cell adhesion in metastasis [127] and immune responses [35]. 
Sulfatide was shown to bind P-selectin during adhesion and invasion of MC-38 cancerous 
cells injected in mice [124], which was significantly diminished when the sulfate group 
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was cleaved. During infiltration of monocytes into inflamed kidney during unilateral 
uretral obstruction, sulfatide act as a binding ligand to L-selectin to permit monocyte 
adhesion. This interaction was disrupted in CST 
-/- 
mouse where the monocytes were 
unable to infiltrate the kidney during inflammation due to the inability of L-selectins on 
monocytes to interact with their ligand [35]. The potential role of sulfatide in cancer 
metastatic may not be restricted to its interaction with different extra cellular matrix 
proteins but could also be due to their ability to interact with hepatocyte growth factors 
[128], cytokines and their receptors [129] as well as regulation of cytokine signaling 
(CXCR4) [130] and NF-KB signaling [131]. The importance of sulfatide binding a 
number of ligands, makes them a potential target for investigative therapeutics. In a study 
conducted in endometrial carcinoma patients, medroxyprogesterone acetate 
(progesterone) was able to reduce expression of sulfatide ligand on the surface of 
cancerous tissue, which may reduce their adhesion laminin and reduce the chances of 
invasion and metastasis [132]. The sulfatide binding to some of these ligands makes them 
a potential target for investigative therapeutics. In a study conducted in endometrial 
carcinoma patients, medroxyprogesterone acetate (progesterone) was able to reduce 
surface expression of sulfatide ligand and on cancerous tissue, which may reduce their 
adhesion laminin and reduce the chances of invasion and metastasis [132]. 
 
 
1.6 Systems biology analysis of sphingolipid biosynthesis 
Given the structural diversity of sphingolipids and the complexity of their 
biosynthesis pathway, application of systems biology and data integration approaches 
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may provide insight into their alterations. Comparison of differences in individual gene 
expression (or enzyme activity) with corresponding metabolites from previous studies 
have revealed interesting correlations. For example, elevated expression of mRNA for 
GD3 synthase has been correlated with the amounts of GD3 in melanoma cell lines [133]. 
Conversely, reduction of C18 ceramide (Cer) in head and neck cancer correlates with 
lower CerS1 and abnormal growth control [134].   
The wide availability of high throughput gene expression platforms have made it 
feasible to measure mRNA abundance of multiple genes and more than 10000 microarray 
datasets are accessible through public repositories such as NCBI GEO [135] , Array 
express [136] and Oncomine [137]. The analysis of gene expression from published 
datasets could help identify alterations in sphingolipid composition which can be 
evaluated by mass spectrometry or though published literature. However, the large 
number of genes, and the existence of multiple branch points in sphingolipid biosynthesis 
pose challenges that can best be addressed with the aid of computational tools that can 
automatically define relationships between different omics datasets.  
Pathway maps prepared by Kyoto Encyclopedia of Genes and Genomes (KEGG) 
have played a critical role in studies of metabolic pathway as they provide information 
about the relationship between enzymes and compounds. However these maps for 
sphingolipid biosysnthesis are have not been updated and remain incomplete and not 
specific to mammals. Despite these short comings they have been used in number of 
bioinformatics and genomics application for gene expression analysis such as GenMapp 




 Despite the increasing knowledge about the regulation of sphingolipid 
biosynthesis, significant challenges remain in the study of these compounds due to their 
structural diversity and complex metabolic pathways. One of the problems facing 
researchers is the absence of accurate pathway maps to visualize differences in the 
expression of transcripts encoding different steps of the pathway and methods to predict 
alterations sphingolipid biosynthesis. Another challenge is the lack of knowledge about 
the transcripts encoding some of the biosynthetic enzymes. Questions also remain about 
the molecular abnormalities associated with models used to experimentally study 
sphingolipid biosynthesis.   
 
This thesis demonstrates the first broad application of bioinformatics and data 
mining to study sphingolipid biosynthesis. In chapter 2 we describe the preparation of 
mammalian sphingolipid biosynthesis pathway maps for simultaneous visualization of 
gene expression and metabolite differences. These pathway diagrams were applied to 
cancer gene expression datasets in chapter 3, to compare correlation between transcript 
and sphingolipid alterations as well as predict novel metabolic changes in cancer cells. 
Chapter 4 describes ongoing studies and published reports that have used the gene 
expression pathway maps prepared during this dissertation. In chapter 5 we demonstrate 
the discovery of gene encoding 3-Ketosphinganine reductase and analyze the effect of the 
absence of FOXC1, a putative transcription regulator of the enzyme.  In chapter 6, we 
employed sequence analysis and homology modeling to identify the reason for the 
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abnormal biosynthesis of sphingolipids in the LY-B cell lines, a model for defective de 
























PREPARATION OF SPINGOLIPID PATHWAY MAPS TO 




Sphingolipids are a structurally diverse family of molecules (www.lipidmaps.org) that 
modulate cell functions that are abnormal in cancer, such as growth, adhesion, migration 
and survival.  Because these compounds and their metabolic pathways are highly 
complex, it is difficult to analyze all of the subspecies associated with cancer.  A useful 
approach might be to utilize gene expression datasets to predict metabolic changes and 
direct attention to particular sphingolipids for analysis. To this effect an updated list of 
genes that facilitate the biosynthesis of both early as well as higher order 
glycosphingolipids was prepared. Using their input and an open access pathway browser, 
Pathvisio v1.1, updated and expanded maps to visualize data from analyses of gene 
expression and sphingolipid metabolites were prepared. In addition, perl scripts were 
developed for extraction and formatting data for pathway visualization are available 
through this study.  
 
2.2 Introduction 
 Sphingolipids are bioactive lipids that have been shown to be differentially 
regulated in diseases such as cancer [8, 9]. However, due to the wide diversity and the 
complexity of their metabolic pathway it is not feasible to characterize differences in all 
 22 
subspecies. With greater access to public gene expression data [135, 136], it would 
feasible to use this wealth of information to predict and study sphingolipid alteration. 
This approach has been applied to specific steps of sphingolipid metabolism: for 
example, elevated expression of mRNA for GD3 synthase has been correlated with the 
amounts of GD3 in melanoma cell lines [133]. Conversely, the finding of differences in 
the amounts of particular sphingolipid subspecies has directed attention to altered gene 
expression. For example, reduction of C18 ceramide (Cer) in head and neck cancer 
correlates with lower CerS1 [134] and elevation of GalCer, LacCer, Gb3Cer in drug 
resistant ovarian cancer cells [138] were accompanied by changes in expression of 
GalCer synthase and LacCer synthase.   
 Nonetheless, there is currently no accurate pathway map for the visualization of 
datasets for large categories of genes and metabolites involved in sphingolipid 
biosynthesis. Therefore, the goal of these studies was to develop a tool for this purpose. 
Using an open access pathway browser, Pathvisio v1.1 [139], updated and expanded 
maps to visualize data from analyses of human gene expression and sphingolipid 
metabolites were prepared. In addition, we prepared a list of preselected gene probes 
associated with sphingolipid biosynthesis and complementary perl scripts for efficient 
retrieval and formatting of gene values. The results of pathway visualization could be 
used for targeted lipidomic analysis using techniques such as mass spectrometry. 
 
2.3 Methods 
2.3.1 Modification of Pathvisio v1.1 and construction of sphingolipid pathway maps 
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An open source java software, Pathvisio v1.1 [139] was selected for the 
construction of pathway maps for different branches of sphingolipid biosynthesis and the 
visualization of differentially expressed genes. To differentiate metabolites from genes, 
the program source code was modified to display metabolites as circular objects, while 
genes retained the rectangular shape. 
   New pathway maps were constructed to complement the features of Pathvisio v1.1 by 
altering KEGG pathway diagrams to include metabolite identifiers at the nodes, while the 
genes were updated to reflect new discoveries and changes in nomenclature. Some of the 
prominent changes in the sphingolipid pathway maps are listed as follows; the addition of 
ceramide synthase gene isoforms (CerS1-6) [14-18], dihydroceramide desaturase 
(DEGS1, DEGS2) [19] and alpha(1,2)fucosyltransferases (FUT1 and FUT2) [79]. The 
layout of the backbone biosynthesis map was modified to differentiate changes in 
sphingolipids with dihydroceramide backbones, and another branch for the synthesis of 
phyto-sphingolipids was included. Updated  pathway maps for sphingolipid backbone, 
gangliosides, globoseries, Lacto-series and Neo-lacto-series biosynthesis can also be 
obtained from the wikipathways database [140].  
 
2.3.2 Selection of gene probes 
 To identify the best probes for sphingolipid genes , the sequences of all probes 
directed to individual transcripts were retrieved from the Affymetrix Netaffx tool [141] 
and compared to the mRNA using the Blat search [142] in the UCSC genome browser 
[143]. The probe that recognized the catalytic transcript and hybridized nearest to its 3‟ 
UTR was selected to represent the gene for pathway model visualization, while others 
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were excluded. The procedure was repeated for all sphingolipid genes for Affymetrix 
chips HG-U95 A-E and HG-U133 plus 2 (Appendix A).  
2.3.3 Perl algorithm for extraction of expression values 
 A Perl script was written to search and extract gene expression values for 
sphingolipid related transcripts. This program transforms the list of probe IDs or Gene 
IDs into an array, and then searches for similar objects in a normalized gene expression 
data file, where the rows represent probe IDs and columns individual experiments. The 
loop function efficiently extracts values and writes the matching sphingolipid gene 
expression values into a text file, which is used to calculate gene fold changes. A copy of 
the Perl script and instructions for use are provided in Appendix A. 
2.4 Results 
2.4.1 Summary of the sphingolipid biosynthetic pathway as the basis for 
construction of gene expression pathway maps  
The following summary described the initial steps of sphingolipid biosynthesis as 
illustrated in Figure 2.1 (Detailed description of the pathway can be obtained from a 
previous article [1]), and the genes references for individual steps are listed in Table 2.1.  
The pathway is initiated by the condensation of serine and palmitoyl-CoA by serine 
palmitoyltransferase (SPT, gene annotation: SPTLC 1, 2 and 3) (shown in the upper left 
corner of Fig. 2.1) to produce 3-ketosphinganine (3KSa), which is reduced to sphinganine 
(Sa) by 3KSa reductase (3KSR, gene annotation:  FVT1).  Sa is either acylated by one of 
the ceramide synthases (CerS) to dihydroceramide (DHCer) or phosphorylated by 
sphingosine kinase (SphK, gene annotated: SPHK1 or 2) to Sa 1-phosphate (Sa1P) 
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(which can be terminally degraded to hexadenanal, C16:0-al, and ethanolamine 
phosphate, EP, by a lyase, SGPL1) (Fig 2.1).  DHCer is at another branchpoint of the 
pathway and is either desaturated to Cer (by DHCer desaturase 1 or 2, gene annotation: 
DES1 and DES2), hydroxylated to 4-hydroxyDHCer (also called phytoCer, by DES2) 
[19], converted to a more complex dihydrosphingolipids, as will be discussed later, or 
hydrolyzed to Sa by ceramidases (ASAH 1-3, 3L and PCHA). For most cells, the major 
route is thought to be desaturation to Cer because Cer is the major lipid backbone of most 
complex sphingolipids [1, 10].  Cer is used for the biosynthesis of SM by SM synthases 
(gene annotation: SMS1 or 2) [144], glucosylCer (GlcCer) by GlcCer synthase (gene 
annotation: UGCG), galactosylCer (GalCer) by GalCer synthase (gene annotation: 
UGT8), or Cer 1-phosphate (Cer1P) by Cer kinase (gene annotation: CERK).  Cer is also 
hydrolyzed by ceramidases (gene annotation: ASAH1-3,3L and PCHA) to sphingosine 
(So) which can be phosphorylated to S1P and terminally degraded to hexadenenal, 
C16:1-al, and EP, as shown in Fig. 2.1.  Also shown on the pathway in Fig. 2.1 is a 
protein, CERT (gene annotation: COL4A3BP), that participates in Cer transport for the 
biosynthesis of SM, CerP and GlcCer.  The headgroup additions are circumscribed by a 
dashed line in Fig. 1 because these enzymes can sometimes accommodate the other types 
of ceramide backbones (e.g., DHCer and PhytoCer), therefore, for simplicity, these steps 
have not been shown explicitly for those branches of the pathway in Fig. 1.  Also shown 
in Fig. 1 are the sphingomyelinases (SMase; gene annotation: SMPD1-3) which are 
responsible for degradation of SM to Cer.  GlcCer is further glycosylated to lactosylCer 
(LacCer) by LacCer synthase (gene annotation: B4GALT6), which is the branch point for 
the five families of complex glysosphingolipids in the five so-called root structure series 
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(globo-series, isoglobo-series, ganglio-series, lacto-series and neo-lacto-series), which 
will be discussed later.  GalCers can be sulfated by sulfatide transferase (gene annotation: 
GAL3ST1) to produce sulfatides (ST). 
In addition to this pathway overview, there are additional variations in the lipid 
backbones that are difficult to depict in a simple diagram (a discussion of an alternative 
graphical display format can be found in [1, 10] ), such as chain length of sphingoid base 
and the fatty acid distribution of ceramide backbones. Different isoforms of the first 
enzyme of the pathway (SPT) have been linked to these alterations. 
 
 In sphingoid base, where the SPTLC2 was shown to synthesize C18 bases, the 
newly identified SPTLC3 subunit has been shown to produce sphingoid base of C16 
chain length (Fig 2.1, upper left corner). Similarly, ceramide synthase isoforms (CerS1-6, 
Fig 1 lower panel) facilitate the selective N-acylation of sphingoid bases to produce 
dihydroceramides (DHCer) with different N-acyl chain lengths [14-18].  These CerS 
isoforms either possess narrow substrate specificity (Eg CerS 5 and 1) or broad chain 
length specificity such as CerS 6, 2, 4 and 3 (Fig 2.1, lower panel). The alterations of Cer 
subspecies has gained prominence due to recent findings that elevation in C18-Cer 
caused by overexpression of CerS1 induced growth arrest in head and neck small cell 
carcinoma cells [134]. 
Another factor that can influence fatty acid composition of ceramides is the 
abundance of the different fatty acyl-CoAs (produced by fatty acid elongases, gene 
annotation: ELOVL 1-7) [145] and their desaturated subspecies (catalyzed by stearoyl-
CoA desaturase, gene annotation: SCD) [146] since they are essential precursors of 








Fig 2.1. Early steps of sphingolipids biosynthesis The pathway begins with the 
condensation of serine and palmitoyl-CoA by serine palmitoyltransferase (SPTLC) to 
produce 3-ketosphinganine (3KSa), which is reduced (by 3KSa reductase, 3KSR) to 
sphinganine (Sa). Dihydroceramide (DHCer) synthases (CerS 1-6) N-acylate Sa with 
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different fatty acyl-CoA (R‟) to produce DHCers, which are converted to ceramides (Cer) 
or Phyto-Cer by DHCer desaturases (DES1,2). Substitution of the 1-OH with different 
head groups (R”) produces Cer 1-phosphate (Cer1P by Cer kinase, CERK), 
sphingomyelin (SM by SM synthase, SMS1,2), galactosylceramide (GalCer by GalCer 
synthase, UGT8) and glucosylceramide (GluCer by GluCer synthase, UGCG), which can 
be further metabolized to sulfatide (ST by ST transferase, GAL3ST1) and 
lactosylceramide (LacCer by LacCer synthase, B4GALT6), respectively. CERT is a 
transporter of Cer from the ER to Golgi and is thought to play a role in the synthesis of 
SM, Cer1P and GluCer.  These headgroup modifications are shown for Cer in the area 
circumscribed by a dashed line (complex sphingolipids) and also pertain to DHCer, 
Phyto-Cer and other backbones. Also shown is the catabolism of Cer to sphingosine (So) 
(and analogous DHCer to Sa) by ceramidase (ASAH1-3), phosphorylation by So (Sa) 
kinases (SPHK1,2) to So 1-phosphate (S1P) (and Sa to Sa1P), and cleavage by S1P lyase 
(SGPL1) to ethanolamine phosphate (EP) and hexadecanal (C16:0al for Sa1P) and 
hexadecenal (C16:1al for S1P).  The lower panel illustrates the synthesis of the precursor 
fatty acyl-CoA by a combination of fatty acid elongases (ELOVL 1-7) and stearoyl CoA 
desaturase (SCD), and their utilization for the N-acylation of sphingoid bases by different 
CerS isoforms (CerS1-7).  
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Table 2.1 List of genes involved in de novo sphingolipid biosynthesis.  
Gene ID  Gene Name Reference 
SPTLC1, SPTLC2, SPTLC 3 
Serine palmitoyltransferase subunits (1, 2 & 
3) 
[147] 
KDSR, 3KSR, FVT1 3-Ketosphinganine reductase [148] 
CerS1, CerS2, CerS3, CerS4 
Cers5, CerS6 Ceramide synthase (1 to 6) 
[14-18] 
SPHK1, SPHK2 Sphingosine kinase (1,2) [149] 
SGPL1 Sphingosine 1-phosohate lyase [150] 
 DES1, DES2 , DEGS1, 2 Dihydroceramide desaturase (1 & 2) [19] 
ASAH1, ASAH2, ASAH3, 
ASAH3L, PCHA  
Ceramidases (Acid, neutral, 
phytoceramidase) 
[151-155] 
SMS1,SMS2, SMSr,  Sphingomyelin synthase (1, 2 and atypical)  
[144, 156] 
UGCG, Gba Glucosylceramide synthase  
[157] 
UGT8, CGT  Galactosylceramide synthase [158] 
CERK Ceramide kinase [159, 160] 
CERT Ceramide transporter [161, 162] 
SMPD1, SMPD2 ,SMPD3, 
SMPD4 Sphingomyelinases (Acidic, neutral) 
[163, 164] 
B4GALT6 Lactosylceramide synthase [165] 
GAL3ST1 galactose-3-O-sulfotransferase 1 [35] 
ELOVL 1-7 Fatty acid CoA elongases (1 to 7) [145] 
SCD Stearoyl CoA desaturase [146] 
ssSPTa, ssSPTb  Small subunits of SPT  [166] 
The table lists alternative gene abbreviations and complete names for genes encoding 






2.4.2 Construction of gene expression pathway maps for human and mouse 
sphingolipid biosynthesis   
Based on the current understanding of sphingolipid biosynthesis discussed above, 
updated pathway maps were prepared to visualize gene expression and metabolites 
differences in de novo sphingolipid biosynthesis using Pathvisio v1.1 [139] (Fig. 2.2). In 
addition, pathway maps to visualize mRNA abundance relevant to biosynthesis of higher 
order glysosphingolipids have been prepared for ganglio-series (Fig. 2.3) and globo-
series, (Fig. 2.4). The associated gene references for higher order glycosphingolipid 
biosynthesis are provided in Table 2.2.  
 
 
2.4.3 Preparation of data for visualization in sphingolipid gene expression pathway 
diagrams  
To visualize differences in mRNA abundance pertinent to the sphingolipid 
biosynthesis pathway, published gene expression datasets for cancer cells and normal and 
tumors [167-169] were obtained from public microarray repositories [135, 136] . 
Platform specific tools were used to normalize raw expression values for samples within 
studies (as discussed in methods section). A perl script was written (Appendix A) to sort 
out expression values for transcripts involved in sphingolipid biosynthesis, and fold 
differences were computed by either taking the ratio between two conditions (such as two 
cell lines or cancer stages), or by normalizing the individual gene expression by the 
average among all samples (in the case of multiple cell lines). The fold differences 
between conditions were visualized by updated sphingolipid biosynthesis pathway maps 






Fig 2.2 Illustration of early step of sphingolipid biosynthesis in Pathvisio v1.1. The 
de novo sphingolipid biosynthesis pathway map was prepared using Pathvisio v1.1 [139]. 
The rectangular boxes represent the genes while the circles depict the metabolites. 
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Fig 2.3 Illustration of ganglio-series gene expression pathway map in Pathvisio v1.1. 
The ganglio-series biosynthesis pathway map was prepared using Pathvisio v1.1 [139]. 













Fig 2.4 Illustration of globo-series gene expression pathway map in Pathvisio v1.1. 
The globo-series biosynthesis pathway map was prepared using Pathvisio v1.1 [139]. The 





Table 2.2 List of genes involved in higher order glycosphingolipids biosynthesis.  
 
Homo sapiens Gene Name Abbreviation References 
Gene    



















β-1,4-galactosyltransferase IIII β4GalT-III,  [171] 
    
B4GALT4 
β-N-acetylglucosaminyl-glycopeptide 
β-1,4-galactosyltransferase IV β4GalT-IV  
B4GALT5 
β-N-acetylglucosaminyl-glycopeptide 
β-1,4-galactosyltransferase V β4GalT-V [172]  
B4GALT6 
β-N-acetylglucosaminyl-glycopeptide 
β-1,4-galactosyltransferase VI β4GalT-VI [173]  
B3GALT1 β3-galactosyltrasferase I β3GalT-I  
B3GALT2 β3-galactosyltrasferase II β3GalT-II [174] 
B3GALT4, GalT4, 














(iGnT) β3GalNAcT, iGnT [177] 
β3GlcNAcT2    
β3GlcNAcT3    
β3GlcNAcT4    
β3GlcNAcT5    
IGnT 
β6-N-Acetylglucosaminyltrasferase 











synthase  [179] 
 Histoblood group A transferase  [180] 
 Histoblood group B transferase   
Forssman 
synthase Forssman Glycolipid Synthase α3GalNAcT [181, 182] 
 para-Forssman Glycolipid Synthase  





Fut1, Fut2 α1/2-Fucosyltransferase FUT1, H, HH, HSC [183] 
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Table 2.2 continued 
Homo sapiens Gene Name Abbreviation References 
FUT2  FUT2, SE, Se2, sej [184] 
FUT3, Fuc-TIII α3/4-Fucosyltransferase 
FUT3, Lewis 












FUT7, Fuc-TVII α3-Fucosyltransferase-VII FUT7 [189] 
FUT9, Fuc-TIX α3-Fucosyltransferase-IX FUT9, FUC-TIX [190, 191] 
 Sialyltransferase 3 SAT-III  




ST6GALNAC3 ST6GalNAc-III STY [195] 
ST6GALNAC5 ST6GalNAc-V GD1α synthase [196] 












B3GAT1 HNK-1 Glucuronlytransferase  [201] 
 HNK-1 Sulfotransferase HNK-1 SulfoT [202]  
GAL3ST1, CST βGal 3-Osulfotransferase-1 Gal3ST-1 [35] 
A4galt, Gb3 
synthase 






acetylgalactosaminyltransferase Globoside synthase [204] 
SLC33A1, 
ACATN O-Acetyltransferase  [205] 
The table list the genes involved in the biosynthesis of glycosphingolipids of the ganglio-
series, globo-series, lacto-series and neo-lacto-series with suitable references. 
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The presence of multiple probes for individual transcripts and large category of 
transcripts posed a challenge during the analysis. To address the former, probes specific 
to the 3‟ UTR of the mRNA were chosen by a Blat search [142] of the UCSC genome 
browser [143]. A list of the optimum probes for sphingolipid biosynthesis in human HG-
U133 Plus2 and HG-U95 affymetrix gene chips is provided in Appendix A. In case of the 
latter, a search algorithm was written in perl (Appendix A) to sort out the expression 
values for the optimum probes using the list of preselected probes.  
 
2.5 Conclusion 
 This tool facilitates the visualization of differential gene expression in 
sphingolipid biosynthesis pathway using public or in-house transcriptomic data. 
Predictions using these mammalian specific pathway diagrams can help direct attention 
to sphingolipid alterations in specific branches of the metabolic pathway. In addition, 
these maps also serve as a resource for comparative analysis of genomic and 
metabolomic data. 
 






PREDICTION OF SPHINGOLIPID ALTERATIONS IN CANCER 
CELLS LINES, TUMORS AND NORMAL TISSUE USING GENE 




Sphingolipids play critical roles in cancer processes and their composition differs 
in tumors. However, it is difficult to characterize differences in all sphingolipid 
subspecies due to the complexity of their metabolic pathway and their wide structural 
diversity. Pathway visualization of gene expression data could help predict altered 
branches of sphingolipid biosynthesis. Therefore, the updated pathway diagrams were 
applied to data for cancer cell lines, tumors and normal tissues from published literature 
and analyses described here, which revealed significant relationships. For example, 
differences in gene expression for two breast cancer cell lines, the highly metastatic 
MDA-MB-231 versus MCF7 cells (representing estrogen receptor, ER, negative and 
positive cells, respectively), predicted that sphingolipid biosynthesis would be lower for 
MDA-MB-231 cells, which was confirmed by labeling studies. MDA-MB-231 cells also 
had lower expression of DES2, the hydroxylase that produces phytoceramides, and mass 
spectrometric analysis found lower phyto-sphingomyelins. In addition, gene expression 
differences between invasive ductal carcinoma and normal ductal breast tissue predicted 
elevated SSEA3 and Globo-H antigen in breast tumors, and this is consistent with 
published results. Comparison of available data for a wide range of cancer types revealed 
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a 72.8 % probability of match between the gene expression data and the sphingolipid 
composition (P < 0.001 by the Fishers exact test). The tool was also used to explore the 
metabolic implications of differences in gene expression for ER-negative versus ER-
positive breast cancer cells identified by traditional hierarchical clustering. In conjunction 
with these studies, pathway maps for the panel of 59 human cancer cell lines (the NCI-
60) have been provided in the supplement for further study. These findings demonstrate 
that a pathway visualization map can facilitate the integration of two types of “omic” 
technologies (“transcriptomics” and “sphingolipidomics”) to predict and identify 
correlations relevant to cancer, which might lead to a better understanding of tumor 





Sphingolipids and glycosphingolipids (GSL) are structurally diverse family of 
compounds that are characterized by a sphingoid base backbone that can be modified by 
the addition of an amide linked fatty acid and wide range of head groups [1].  
Sphingolipids play important roles in cancer processes, such as growth, survival, 
adhesion, and migration [34], and tumors often display alterations in sphingolipid 
composition [8, 9] and been proposed as cancer markers [76, 79, 81]. Because these 
compounds and their metabolic pathways are highly complex, integration of gene 
expression data with sphingolipid analysis might aid the understanding of the molecular 
changes associated with cancer, and identify novel biomakers. 
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Comparison of gene expression and metabolite differences for specific steps of 
sphingolipid metabolism has identified relationships between mRNA and sphingolipid 
alterations in tumors [133, 134, 138]. However as wide range of gene expression datasets 
have become accessible through public repositories (NCBI GEO [135] , Array express 
[136] and Oncomine [137]), it is now possible to evaluate gene expression differences in 
different branches of sphingolipid biosynthesis using the updated pathway maps using an 
open access pathway browser, Pathvisio v1.1 [139].   
In this study visualization of public gene expression datasets for cancer cell line, 
tumors and normal tissue using sphingolipid biosynthesis pathway maps identified 
substantial agreement between gene expression and metabolite profiles in different 
branches of the pathway. Among the significant findings, prediction of gene expresson 
diffrerences between MCF7 and MDA-MB-231 cells resulted in the identification of 





 MCF7 cells were purchased from ATCC (Manassas, VA), while MDA-MB-231 
cells were provided by Dr. Nathan Bowen (School of biology, Georgia Institute of 
Technology, Atlanta, GA). Cell culture medium was procured from Gibco (Carlsbad, 
CA) and fetal bovine serum was obtained from Hyclone (Logan, UT). U-
13
C labeled 
palmitic acid was obtained from Cambridge Isotopes (Andover, MA). The mass 
spectrometry internal standards were procured from Avanti Polar Lipids (Alabaster, AL), 
while GSL standards were obtained from Sigma (St louis, MO) and Matreya (Pleasant 
Gap, PA ).  All other reagents and solvents were HPLC grade.   
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3.3.2 Selection of DNA microarray datasets and statistical analysis 
In the present study, keyword search was conducted on NCBI GEO [135] , Array 
express [136] and Oncomine [137] for „cancer type‟ or „cancer cell line‟ , and the 
outcomes were examined to identify expression datasets having multiple replicates of 
control and cancer tissues, or all cell lines to be compared.  The Affymetrix expression 
files (.CEL file) for the selected datasets were downloaded and processed by Affymetrix 
expression console v1.1 (Affymetrix, Santa Clara, CA) using the MAS5 algorithm. For 
non-Affymetrix studies the normalized and background corrected expression datasets 
(GDS file, NCBI GEO format) were accessed using the GEOquery package [206] of 
Bioconductor  v1.8 [207], and exported as tab delineated text files. Sphingolipid specific 
gene expression values were filtered using a Perl search algorithm and a list of 
preselected Affymetrix probe ids or Gene ID (see below). The gene expression fold 
change was determined using Excel (Microsoft Inc, Seattle, WA), after which the data set 
was formatted as a Pathvisio input file (comma separated values) with „gene ids‟, „system 
code‟ and „fold change‟. 
 
 
3.3.3 Pathway visualization 
In the modified Pathvisio v1.1 browser, the appropriate gene and metabolite 
database was selected and the expression dataset was created after importing the saved 
input file using the „import expression dataset‟ tab. The color criteria for the expression 
dataset were specified by the „visualization option‟ function. Gene and metabolite 
expression changes were visualized on the pathway maps by opening the pathway 
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diagram and then selecting the saved expression dataset and visualization criteria. A 
detailed tutorial is available at www.Pathvisio.org. The pictures were prepared by 
exporting the images as PDF files; while changes to font colors were performed with 
Corel draw X4 (Mountain view, CA). 
 
3.3.4 Selection and analysis of GSL profiles from literature  
To select sphingolipid metabolite changes in cancer cells and tissues, published 
literature was reviewed through a keyword search of Pubmed and Google Scholar with 
the terms „cancer type/cell name and glycosphingolipids‟. The abstracts of the selected 
manuscripts were manually screened to identify articles that characterize sphingolipids in 
cancer specimens using analytical methods such as thin layer chromatography (TLC) or 
mass spectrometry (MS). In addition, the experimental design and the cancer subtypes 
were verified to match the microarray study. Quantitative data for metabolites were 
directly used to compute fold changes, while changes observed in TLC experiments were 
compared by densitometry analysis of JPEG images using Fluorchem 5500 (Alpha 
Innotech , San Leandro, CA).  
 
3.3.5 Tissue culture and sphingolipid analysis by LC-MS/MS analysis  
The MCF7 and MDA-MB-231 cells were grown in 100 mm tissue culture dishes 
using RPMI 1640 medium containing 5% fetal bovine serum using conditions described 
previously [167]. When the cells reached 80-90% confluency they were washed once 
with PBS solution, before being scraped into screw capped glass test tubes for 
sphingolipid extraction as previously described [208]. An aliquot of the cells was retained 
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from each dish to measure the protein concentration by the BCA assay (Pierce 
Biotechnology, Rockford, IL).  During stable isotope labeling studies, the media was 
supplemented with 0.1 mM [U-
13
C]-palmitic acid complexed with equimolar fatty acid 
free BSA (Calbiochem, Gibbstown, NJ). After 12 or 24 h, depending on the experiment, 
the incorporation of stable isotope into sphingolipids was measured by liquid-
chromatography, electrospray ionization-tandem mass spectrometry (LC ESI-MS/MS) as 
previously described [208].   
Complex sphingolipids and long chain bases were analyzed using ABI 3000 and 
ABI 4000 LC-tandem mass spectrometers (Applied Biosystems, Foster City, CA) as 
described previously [208].  
  
3.3.6 Cluster analysis of breast cancer cell lines  
The gene expression dataset for ER-positive and ER-negative breast cancer cell 
lines were obtained from  NCBI GEO (GSE12777 ) [169] and the „.CEL‟ file were 
processed as previously described.  Expression values for sphingolipid specific genes 
were extracted and the average fold change ER-positive and ER-negative was computed 
by Excel. Genes with significant expression difference (p-value < 0.05) between the two 
groups were compared by unsupervised hierarchical clustering using the average linkage 






3.4 Results and Discussion 
 
3.4.1 Comparison of gene expression and sphingolipid differences between MCF7 
and MDA-MB-231 breast cancer cells 
Gene expression differences between the ER-positive MCF7 and highly metastatic ER-
negative MDA-MB-231 cell lines were compared using published microarray data [167], 
and the ratios of mRNA abundance between the latter and former cells (the numerator 
and denominator, respectively) were visualized by the sphingolipid biosynthetic pathway 
diagrams (Fig 3.1). Analysis of the initial steps of sphingolipid biosynthesis (Fig 3.1) 
predicts that MDA-MB-231 cells have lower expression of SPTLC1 and SPTLC2 (Fig 
3.1, dashed box A), the genes responsible for the first step of de novo sphingolipid 
biosynthesis. In contrast, MDA-MB-231 cells have higher expression of SPTLC3 
compared to MCF7, indicating an elevation of sphingolipids with C16 sphingoid base. 
The map also predicts that MDA-MB-231 cells have lower mRNA for the desaturases, 
SCD (multiple transcript) (Fig 3.1, dashed box B), that converts C18:0-CoA to C18:1-
CoA, which is subsequently elongated to other FA-CoA (C24:1 and C26:1)[210]. This 
visualization also reveals that MDA-MB-231 cells have lower DES2 (Fig 3.1, dashed box 
C), which is responsible for the addition of 4-OH to dihydro-Cer to make phyto-Cer. In 
addition, MDA-MB-231 cells displayed lower mRNA for UGT8 and higher UGCG and 








Fig 3.1. Visualization of transcription and metabolite differences in early steps of 
sphingolipids biosynthesis between MCF7 and MDA-MB-231 cells using and 
expanded pathway map and Pathvisio v1.1. The figure depicts sphingolipid genes 
(indicated as rectangles) and metabolites (circles) that participate in early steps of 
sphingolipid biosynthesis (ref Fig1) prepared in the Pathvisio v1.1 [139]. The updated 
and expanded pathway map was overlaid by gene expression fold change difference 
between MDA-MB-231 and MCF7 cells that were obtained from a previous study [167]. 
Variations in sphingolipid composition (shaded circles) between the two cell lines were 
determined by LC-ESI-MS/MS as previously described [211] and compared to gene 
expression as highlighted by circumscribed dash boxes (A,B, C and D) and are discussed 
in Fig 3-6.  The shade of the box and circles represents the degree of up and down 
regulation as indicated by the color chart.  
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To test the prediction that MDA-MB-231 cells have lower SPTLC1 and SPTLC2, 
which are the primary SPT genes responsible for d18 sphingoid base biosynthesis (Fig 
3.1, dashed box A) and hence lower de novo sphingolipid biosynthesis, cells were 
incubated with [U-
13
C]-palmitic acid and the labeled sphingolipids were extracted and 










MCF7 cells (Fig 3.2A, white bars) (changes at other time points are 
depicted in the figure) . The term [U-
13
C] SL refers to the sum of SL and DHSL which 
have [U-
13
C] palmitate incorporated in both the sphingoid base as well as the N-acyl 
chain as determined by multiple reaction monitoring (MRM).  
 
Another intensity difference between MDA-MB-231 and MCF7 cells was a 
higher expression of SPTLC3, which has been proposed to metabolize a shorter chain 
(d16:1) [12, 13]. Preliminary analysis of the Cer subspecies of these cells using a recently 
developed method [211] indicated that MDA-MB-231 cells had a higher proportion of 
d16:1-Cer (1.85  + 0.4 pmol /10
6 
cells) than (1.09 + 0.16 pmol /10
6 
cells) MCF7 cells (p-







Fig 3.2. Comparison of de novo sphingolipid biosynthesis between MDA-MB-231 
and MCF7 cells with gene expression of serine palmitoyltransferase. The two cells 
were grown as previously described  [167] and incubated with and without 0.1 mM 
[13C]-palmitic acid for 0, 3 and 6hr and the sphingolipids labeled in sphingoid base and 
fatty acid (Dual) were measured by LC-ESI-MS/MS [211]. In parallel experiments, 
unlabelled sphingolipids were also measured in both cell types. A) sum of Dual [13C]-
palmitate labeled complex sphingolipids with SL (Cer) and DHSL (DHCer) backbone, B) 
sum of unlabeled complex SL and DHSL in ceramide, Cer, monohexosylceramide, 
HexCer and sphingomyelin, SM. The significance as indicated by an asterisk was 












To test the predictions of lower mono unsaturated fatty acyl-CoA (FA-CoA) in 
MDA-MB-231 compared to MCF7 cells due to lower expression of the mRNA for SCD 
(Fig 3.1, dashed box B), the FA-CoA were analyzed within the two cells .  MDA-MB-
231 cells have significantly lower amounts of mono-unsaturated fatty acyl-CoA (Fig 
3.3A, black bars, 6.3 + 0.22 pmol C18:1 /10
6 
cells; 1.4 + 0.2 pmol C24:1 /10
6 
cells; 4.6 + 
2.1 pmol C26:1 /10
6 
cells), as compared to MCF7 cell (Fig 3.3A, white bars, 14.3 + 0.6 
pmol C18:1 /10
6 
cells, p-value < 0.001;  5.3 + 1 pmol C24:1/10
6
 , p-value < 0.001; 10.8 + 
0.9 pmol C26:1 /10
6 
cells, p-value < 0.001). In contrast, no significant difference was 
observed in saturated FA-CoAs (Fig 4A, C18:0, C24:0 and C26:0). Furthermore, because 
FA-CoAs are precursors for N-acylation of sphingoid bases, the Cer subspecies were also 
evaluated. MDA-MB-231 cells have significantly lower amounts of Cer with mono-
unsaturated fatty acids (Fig 3.3B, black bars, 0.28 + 0.07 pmol C18:1-Cer /10
6 
cells, 24.8 
+ 4.5 pmol C24:1-Cer / 10
6 
cells and 3.88 + 0.64 pmol C26:1-Cer / 10
6 
cells), as 
compared to MCF7 cell (Fig 3.3B, white bars, 0.21 + 0.04 pmol C18:1-Cer / 10
6 
cells, p-
value = 0.02; 7.07 + 0.95 pmol C24:1-Cer / 10
6 
cells, p-value < 0.001; and 0.5 + 0.07 
pmol C26:1-Cer / 10
6 
cells, p-value < 0.001). Also consistent with the absence of 
differences in saturated fatty acids, no change was observed in their corresponding Cer 
subspecies (Fig 3.3B; C18:0-Cer, C24:0-Cer and C26:0-Cer).  These findings suggest that 







Fig 3.3. Comparison of gene expression differences of stearoyl CoA desaturase with 
the composition of fatty acyl CoA and ceramide chain lengths. MDA-MB-231 and 
MCF7 cells were grown as previously described [167] and the fatty acyl-CoA (FA-CoA) 
and ceramides (Cer) were measured by LC-ESI-MS/MS [208, 212]. A) composition of 
saturated and monounsaturated FA-CoA chain lengths, B) N-acyl chain distribution of  
Cer corresponding to the FA-CoA measured in A. The changes in the metabolites were 
compared to differences in the expression of steroyl CoA desaturase (SCD), fatty acid 
elongases (ELOVL) and ceramide synthase (CerS) (Fig 2, Box B). The significance as 
indicated by an asterisk was determined by a t-test at p < 0.05 for n = 6. The shade of the 
box represents the degree of up and down regulation as indicated by the color chart.  
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To test if the lower production of the mRNA for DES2 would cause lower 
amounts of phyto-sphingolipids in MDA-MB-231 compared to MCF7 cells (Fig 3.1, 
dashed box C), these subspecies were analyzed by LC-ESI-MS/MS.  MDA-MB-231 cells 
had 1.4 + 0.25 pmol phyto-Cer / 10
6
 cells, 0.06 + 0.02 pmol phyto-HexCer / 10
6
 cells and 
0.6 + 0.05 pmol phyto-SM / 10
6
 cells (Fig 3.4, black bars, different scale) and all of 
which were higher in MCF7 cells 6 + 1.4 pmol phyto-Cer / 10
6
 cells (p-value < 0.001), 
0.21 + 0.036 pmol phyto-HexCer / 10
6
 cells (p-value < 0.001) and 17.6 + 1.9 pmol phyto-
SM / 10
6
 cells (p-value < 0.001) (Fig 3.4, white bars, different scale).   
 
Furthermore, the pathway diagram predicted lower biosynthesis of GalCer due to 
lower expression of UGT8 and higher GluCer due to higher UGCG in MDA-MB-231 
compared to MCF7 cells (Fig 3.1, dashed box D). Consistent with these predictions, 
MDA- MB-231 cells have 0.6 + 0.6 pmol/10
6
 cells GalCer (Fig 3.5, left panel black 
bars), as compared to 9 + 2 pmol GalCer /10
6
 MCF7 cells (p-value < 0.001) (Fig 3.5, left 
panel white bars). In contrasts, no significant difference in GlcCer was measured between 
the two cell lnes (60.9 + 11.4 pmol GlcCer /10
6
 MDA-MB-231 cells and 66.1 + 10.1 
pmol GlcCer /10
6
 MCF7 cells, p-value = 0.41). In addition, the higher expression of 
LacCer synthase matched elevated amounts of LacCer reported in MDA-MB-231 











Fig 3.4. Comparison of changes in the DES2 expression with differences in Phyto-
sphingolipids. Shown is the LC-ESI-MS/MS comparison of phyto-sphingolipids (phyto-
SL), phyto-ceramide, phyto-Cer, phyto-monohexosylceramide, phyto-HexCer and phyto-
sphingomyelin, phyto-SM (different scale) for MDA-MB-231 and MCF7 cells. The 
significance as indicated by an asterisk was determined by a t-test at p < 0.05 for n = 6. 
The metabolites were compared to gene expression differences in dihydroceramide 
desaturase 2 (DES2), where the shade of the box represents the degree of up and down 














Fig 3.5. Pathway visualization of changes in gene expression and complex 
sphingolipids. The figure compares gene expression differences in GluCer synthase, 
UGCG and GalCer synthase, UG8 with LC-ESI-MS/MS analysis of GluCer and GalCer 
within MDA-MB-231 and MCF7 cells as previously described [211]. The significance as 
indicated by an asterisk was determined by a t-test at p < 0.05 for n = 6. LacCer synthase, 
B4GALT6 expression between the two cells was compared with densitometry analysis of 
LacCer quantization from a previous study [82]. The shade of the box and circles 
represents the degree of up and down regulation as indicated by the color chart.  
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3.4.2 Correlation of gene predictions and metabolite analysis in breast tumor tissues 
In addition to changes in gene expression observed in breast cancer cell lines, 
gene expression differences between invasive ductal carcinoma (IDC, breast tumors) and 
normal ductal tissue were compared using a previously published microarray dataset 
[168]. Visualization of the ganglioside biosynthesis pathway gene differences (Fig. 3.6) 
predicted higher GM3 synthase, B4GALNT1 (responsible for GM2, GD2 and GT2 
synthesis), ST3gal2 (responsible for GD1a, GT1b and GQ1c synthesis) and ST8SIA5 
(responsible for GT3, GT1a, GQ1b and GP1c synthesis). In agreement with these 
predictions, higher quantities of GM3 have been previously reported in IDC tissue (Fig 
3.6, shaded circles) [78]. On the other hand, GD3, and N- and O-acetyl GD3 and GT3 are 
also higher, but the mRNAs for the proximal enzymes are not elevated. Therefore the 
changes in these sphingolipids may be result of higher levels of the precursor, GM3 (Fig 
3.6, shaded circles) [78]. Also consistent with gene predictions, serum from IDC patients 
have been shown to have significant elevation in GD1b, GT1b and GQ1b (Fig 3.6, circles 
with colored edges) as compared to healthy volunteers [81]. 
   
 
Comparison of the globoseries biosynthesis pathway map for normal ductal tissue 
versus IDC (Fig 3.7) showed that B3GalT5 and Fut2 (which synthesize SSEA-3 and 
Globo-H antigen, respectively) were higher. Consistent with predictions previous reports  
have established elevated quantities of SSEA-3 and Globo-H antigen in 77% and 61% of 




Fig 3.6. Comparison of ganglioside biosynthesis gene expression deference between 
invasive ductal carcinoma and normal ductal tissue to corresponding metabolites.  
Gene expression differences between the two breast cancer stages were visualized from a 
previous study [168] using updated ganglioside biosynthetic maps in Pathvisio v1.1 
[139]. Ganglioside measurements reported in similar tumors (circles with solid shade) 
[78] and patient serum (circles with colored edges) [81] were compared to mRNA 
abundance .  The shade of the box and circles represents the degree of up and down 







Fig 3.7. Comparison of globo-series biosynthesis gene expression deference between 
invasive ductal carcinoma and normal ductal tissue to corresponding metabolites.  
This figure compares gene expression differences between normal and invasive ductal 
carcinoma (IDC) from a previous study [168] using updated KEGG pathway maps for 
globo-series biosynthesis to metabolite changes previously reported using flow cytometry 
[79]. The shade of the box and circles represents the degree of up and down regulation as 
indicated by the color chart.  
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3.4.3 Comparison of the frequency of gene and sphingolipid alterations in cancers  
 To determine whether mRNA abundance concur with metabolite differences, 9 
gene expression datasets for which corresponding metabolite data was available (for a 
total of 80 observations, including the present study) were analyzed. Evaluation of 
positive and negative correlations between gene expression differences and metabolite 
amounts revealed 38 instances in which both increased, whereas in 21 both decreased, for 
a total of 59 positive correlations (Fig 3.8, Table 3.1). In 22 cases, gene and metabolite 
changes showed opposing outcomes (a negative correlation). In 10 instances gene 
expression remained unchanged inspite of alterations in metabolites. Thus, there was 
72.8% correlation between gene expression and sphingolipid differences, which was 
statistically significant at p-value < 0.001 by the Fisher‟s exact test (Fig. 3.8).  
 
 
3.4.4 Sphingolipid biosynthesis gene expression differences between ER negative 
and ER-positive breast cancer cells  
This technique was extended to identify gene expression differences that are 
observed between multiple breast cancer cell lines [169]. Pathway map comparison of 
average gene expression differences in 31 ER-negative and -positive breast cancer cell 
lines showed that the former had higher CERK, UGT8, GD3 synthase and Forssman 
antigen synthase and lower SPTLC2, CerS6 and DES2 (Fig 3.9 A and B).These findings 
concur with previous reports that indicated higher CERK, UGT8 and GD3 synthase and 








Fig 3.8. Statistical comparison of gene expression differences with metabolite 
amounts. The chart displays the results from survey comparing ten different gene 
expression datasets with corresponding sphingolipids. G(i) and G(d) indicate an increase 
and decrease in gene levels, while M(i) and M(d) indicate increase and decrease in 
metabolites. The significance of agreement and disagreement  between genes and 
metabolites was measured by the Fisher‟s Exact test (p-value = 0.01).
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Table 3.1. Comparison of gene expression and glycosphingolipid differences for nine 
cancer datasets.  
















11 1 2 3 
IDC/ normal 
ductal 
[168] [78-81] 5    
Gliosarcoma [215] [69] 2 1 1  
GBM/ white 
matter 
[215] [68] 1 3 2 2 
Serious 
ovarian  
[216] [75, 76] 2   1 
Mucinous 
ovarian 
[216] [75, 76] 4   1 
SSEA3/ 
globo-H 
[167] [217] 3 7 5  
Melanoma 
cells 
[133] [133] 6 9 5  
Melanoma [218] [72] 3    
       
Total   38 21 15 7 
 
The table compares the agreement G(i)M(i) and G(d)M(d), and disagreement G(i)M(d) 
and G(i)M(d), between gene expression and sphingolipid differences for nine cancer 
datasets.  G: gene expression differences, M: metabolite difference, (i): higher ratio, and 
(d): lower ratio. The total for each category were used to determine the statistical 












Fig 3.9. Pathway visualization of gene differences between estrogen receptor positive 
and negative cell lines. The sphingolipid pathway diagrams compare the average gene 
expression differences between estrogen receptor positive and negative breast cancer cell 
lines from previous study [169], and were prepared using Pathvisio v1.1 [139]. A) 
Illustrates the gene expression differences in the early steps of sphingolipid biosynthesis 
while, (B) indicates differences in mRNA of ganglioside biosynthesis genes.  The shade 
















Fig 3.10. Comparison of glycosphingolipid biosynthetic gene expression between 
estrogen receptor positive and negative cell line. The heatmap depicts the hierarchical 
clustering of differentially expressed (p-value < 0.05) glycosphingolipid biosynthetic 
genes between the estrogen receptor positive(ER positive) and negative (ER negative) 
breast cancer cell lines obtained from a previous study [169]. The columns represent the 
cell lines and the rows correspond to individual genes. The diagram were prepared using 





gene expression differences standard gene expression approaches such as hierarchical 
clustering and heatmap diagram (t-test, p-value < 0.05, Fig 3.10) revealed heterogeneity 
in between breast cancer cell lines within categories. Such variations might predict 
altered profile of metabolite markers within subcategories of breast cancer type.  
 
3.4.5 Sphingolipid gene expression pathway maps for 59 cancer cell lines  
The supplement for the manuscript has pathway maps based on previously 
published gene expression data [167] for all 59 cancer cells lines in the NCI (NCI-60, 
http://discover.nci.nih.gov/cellminer/) (Appendix B).  From these, further studies could 
explain the possibility of tumor specific changes in sphingolipids as have been illustrated 




This pathway visualization map provides a tool to identify correlations between 
differentially expressed genes and metabolites in the sphingolipid pathway. Since there is 
a growing body of data on differences in gene expression in cancers and other diseases, 
these pathway maps can be used to predict changes in sphingolipid metabolites that can 








DESCRIPTION OF STUDIES EMPLOYING GENE EXPRESSION 
PATHWAY MAPS TO VISUALIZE TO STUDY SPHINGOLIPID 
BIOSYNTHESIS 
The gene expression pathway maps prepared during this dissertation have been used in a 
number of studies to elucidate transcriptional changes in different branches of sphingolipid 
biosynthesis. The studies are listed below.  
 
1) Visualization of gene expression data for sphingolipid and glycosphingolipid metabolism 
and metabolites via a pathway model and its application to cancer. This paper described the 
construction of the pathway maps and its application to cancer datasets. (submitted to BMC 
Systems Biology)  
 
2) Comparison of gene expression differences between normal and ovarian epithelium cancer 
cells predicted elevated amounts of sulfatide and its precursor in cancer tissue which were 
confirmed by LC-ESI-MS/MS (submitted to Molecular Cancer)  
 
3) Study of gene expression differences between mouse embryonic stem cells and embroid 
bodies using the pathway map showed correlation with variation in the fatty acid composition 
of their ceramides (J Lipid Res. 2010 Mar;51(3):480-9).  
 
4) Sphingolipidomics: a valuable tool for understanding the roles of sphingolipids in biology 
and disease. (J Lipid Res. 2009 Apr;50 Suppl:S97-102).  
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5) Pathway visualization of gene expression differences in KDo2 treated mouse macrophage 
cells (RAW264.7) using high throughput qRTPCR agreed with composition of sphingolipid 
and sulfatides. (In collaboration with Dr Kelly Mormon and Lipidmaps)  
 
6) Comparison of gene expression differences in ovarian cancer stem cells versus ovarian 
epithelial cells concurred with results of glycosphingolipids and N-acyl distribution of 
ceramides (study in collaboration with Dr John McDoanald)  
 
7) Visualization of age dependant changes in gene expression in sphingolipid biosynthesis 

















CLONING OF HUMAN 3-KETOSPHINGANINE REDUCTASE AND 
ITS PUTITIVE REGULATED BY FOXC1  
  
5.1 Abstract 
3-Ketosphinganine reductase (3KSR) is the second enzyme of the de novo sphingolipid 
biosynthesis pathway that catalyzes the reduction of 3-ketosphingaine to sphinganine. 
During the preparation of the pathway maps its human transcript was unknown. 
Therefore, based on homology matches to yeast 3KSR transcript, follicular lymphoma 
variant type 1 (FVT1) was identified and cloned. A sensitive HPLC compatible enzyme 
assay was developed to measure 3KSR activity.  Over-expression of FVT1 in Hela cells 
resulted in a 1.8-fold increase in 3KSR activity. Expression of the FVT1 transcript in 
E.coli cells, which lack the enzyme, produced significant 3KSR activity. Furthermore, as 
reports had shown that FOXC1 was a putative transcriptional regulator of FVT1 and Hela 
cells had a defective FOXC1, we measured sphingolipid intermediates of 3KSR in Hela 
and HekSPT1/2 cells. LC-ESI-MS/MS analysis of sphingolipids from the two cell lines 
detected significantly higher amounts of N-acetylated 3-ketosphinganine (3-keto 
dihydroceramide) in Hela cells as compared to Hek SPT1/2 cells. The elevated amounts 
of 3-keto dihydroceramide in Hela cells matched with low expression of FVT1 as 
confirmed by western blot analysis. These results show that FVT1 possess 3KSR activity 





Modern molecular biology techniques have aided in the discovery of a genes encoding 
broad set of sphingolipid biosynthesis enzymes. However, at the outset of my thesis 
research the transcripts encoding some of the biosynthetic enzymes had not been found, 
such as 3-ketosphinganine reductase (3KSR). This enzyme catalyzes the reduction of 3-
ketosphinganine in the de novo sphingolipid biosynthesis pathway. 3KSR activity was 
first found in rat tissues [219]. Because the enzyme is highly expressed, the intermediate 
is rapidly converted [1], but a recent report suggested the discovery of its substrate, 3-
ketosphinganine [220].  At the start of this study the human gene encoding 3KSR was not 
identified despite the discovery of its yeast homolog [221].  
Our work in this chapter focuses on identification of the human 3KSR gene by 
homology to the yeast transcript and its enzymatic verification in human and E.coli cells. 
We further describe the discovery of FOXC1 as a putative transcription regulator of 
3KSR and accumulation of 3-ketodihydroceramides in cells lacking the transcription 






Hela cells were obtained from ATCC, while Hek cells stably over-expressing 
SPT1 and SPT2 (Hek SPT1/2) were obtained from Dr David Ulinger (Johnson and 
Johnson pharmaceutical, Nutley, NJ). Normal human genomic DNA was obtained from 
invitrogen (Carlsbad, CA). The expression vector (pUC18, pCDNA3.0, pEGFP-N1 and 
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pET25b) were purchased from Takara Bio (Mountain view, CA). The cell culture 
medium DMEM and DMEM-F12 was from Gibco (Carlsbad, CA) and fetal bovine 
serum was obtained from Hyclone (Logan, UT). Penicillin G and streptomycin were 
purchased from Sigma (St Louis, MO). The sources for the antibodies were Abnova 
(Taipei, Taiwan) for anti-3KSR, Abcam (Cambridge, MA) for anti-FOXC1 and Ambion 





was purchased from GE healthcare (Piscataway, NJ). All other 
reagents and solvents were of high quality.  
 
 
5.3.2 Cloning of 3KSR and FOXC1 
The human expression sequence tag
 
clone for 3KSR was obtained from Open 
Biosystems (image id 3636291). The clone was sequenced to confirm its match to the 
full-length cDNA sequences
 
of the human FVT1 gene (Genbank accession numbers 
BC008797). Fragments containing the
 
cDNA were amplified by PCR using the forward 
(gatg ctgctgctggctgccgcc) and reverse (gcggcagttttgtctgcattttc ) primers. The purified 
DNA was ligated into to the pUC18 vector, and then subcloned using the introduced
 
restrictions sites into vectors for mammalian (pCDNA3.0 & pEGFP-N1) and bacterial 
(pET25b) expression. The clones were sequenced to validate the orf sequence. 
  Because no clone was available for human FOXC1, the genes was cloned from 
normal human DNA, since the gene lacks any introns [222]. The FOXC1 orf was 
amplified by PCR using forward (cggaccgggcgcgttgccg) and reverse 
(aaacttgctacagtcgtagacgaaag) primers. The amplified product was ligated into pCDNA3.1 
vector for mammalian expression. The sequencing of the clone detected three point 
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mutations (A to G substitution at nt 1329, G to A substitution at nt 975). Our attempts to 
correct them using the GeneTailor site directed mutagenesis kit (Invitrogen) with 
appropriate PCR primers were unsuccessful due to the high GC (80%) content of the 
gene. The three point mutations in the FOXC1 clone were corrected with the help of an 
outside vendor (Mutagenex, Piscataway, NJ). The sequencing of the final clones revealed 
no mutations. 
 
5.3.3 Expression and enzyme activity assay of 3KSR in E.Coli 
His-tagged 3KSR cloned into pUC18 was transformed into the E. coli strain 
(TunerTM (DE3)pLacI) and the protein production was induced by the addition of 1 mM 
isopropyl-1-thio-β-D-galactopyranoside. After growing the cells at 30 
o
C for 5 hr, the 
cells were collected by centrifugation. The expressed protein was obtained following the 
lysis of the cells using a solution mixture containing the BugBuster lysis buffer 
(Novagen), rLysozyme (Novagen), Benzonase Nuclease (Novagen) and protease 
inhibitor cocktail (Roche).   
The 3KSR expressed in E.coli was assayed by adapting a previously developed 
method [221]. 3KSR enzyme assay was initiated by the addition 80 µM 3-
ketosphinganine substrate to a 300 µl of assay mixture containing 1 mg of protein 
(supernatant cell lysate),
 
50 mM Hepes (6.9), 5 mM dithiothreitol, 2.5 mM EDTA and 
NADPH regenerating system (Clontech). After incubating for 10
 
min at 37 °C, the 




5.3.4 Cell culture and enzyme assay of 3KSR in Hela cells 
Hela cells were grown in 100 mm dishes to confluency in DMEM substituted 
with 10% FCS and antibiotics (penicillin and streptomycin) at 37 
o
C in 4% CO2. Cells for 
invitro enzyme activity assay were scrapped in 10 mM phosphate buffer and lysed by 
sonication. The 200 L reaction mixture for the enzyme assay consisted of 100 g of 
protein, NADPH regenerating system, 100 M di-thiothreotol and 5 M 3-keto 
sphinganine made volume with the assay buffer. The reaction was stopped after 10 min 
with addition of 2:1 methanol : chloroform. 5 M C20 sphingosine was added to each 
sample as an internal standard.  
To determine 3KSR activity in transiently transfected Hela, cells were grown in 
six well plates to 50-60 % confluency and transfected with control (pEGFP) or pEGFP-
3KSR using the GeneJuice transfection reagent (Epicenter). The transfection efficiency 
was determined by fluorescence microscopy to be 80%. After 48 hr cells were scraped 
into assay buffer (10 mM phosphate buffer) and the in vitro assay was performed as 
described above.  
 
5.3.5 Extraction of sphingolipid long chain bases (LCB) 
During the extraction of LCB from the assay mixture, 1 ml
 
of CHCl3 and 1 ml 
water were added along with 5 M of C20 sphingosine as an international standard and 
mixed by sonication.
 
The sample was centrifuged, and the upper aqueous layer was 
removed.
 
The lower phase was washed three times with 1 ml of water, drained through a 
small column containing anhydrous sodium sulfate (granular), and dried by speedvac 
(Thermo scientific, Waltham, MA). The
 
extracted LCBs were resuspended in 1 ml of 0.1 
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M KOH in methanol and CHCl3 (2:1) and incubated at 37 C to cleave the 
acylglycerolipids. After the sample had cooled to room temperature, 1 ml each of 
chloroform and water were added. The LCBs were recovered in the chloroform phase, 
washed two times with water, and dried over sodium sulfate column, and the solvent was 
removed by speedvac. 
 
5.3.6 HPLC analysis  
The HPLC analysis of the 3KSR enzyme assay was performed with slight 
modification of a previously reported method for the analysis of free sphingosine [223]. 
Shortly before HPLC analysis the lipid extracts were solubalized in 100 µL of methanol 
by sonication, and derivatized by mixing with 50 µL of o-phthalaldehyde (OPA) solution. 
(The OPA solution was freshly prepared prior to derivatization by mixing 9.9ml 3% boric 
acid solution in water (pH adjusted to 10.5 with KOH) and 0.1 ml of ethanol containing 5 
mg of OPA and 20 µL of beta-mercaptoethanol.) After 5 min of incubation at room 
temperature and the reaction was stopped by addition of 900 µL of mobile phase (10% 
v/v 5mM phosphate buffer in methanol). The LCB were resolved by a mobile phase 
consisting of 10% v/v potassium phosphate (pH 7.0) - methanol using a C18 packed 
column (Waters) and analyzed by a fluorescent detector (Shimadzu) at excitation 340 nm 
and emission 455 nm. The results were analyzed using the CLASS VP chromatography 
data system v4.3 (Shimadzu). 
 
5.3.7 Western blot analysis 
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 Hela cells grown as described above were collected at 80% confluency by 
scraping into PBS solution containing the completemini protease inhibitor cocktail. The 
total cell lysate was incubated with Benzonase Nuclease  (Novagen, Madison, WI) for 
DNA cleavage for 30 min at room temperature, following which equal amounts of 
protein (15 μg) were separated by 12% SDS-PAGE (Pierce, Rockford, IL) minigel (10 
well) in Tris-HEPES-SDS (100mM Tris, 100mM HEPES, pH 8.0, 3 mM SDS) running 
buffer and electrophoresed at 160 volts. The separated proteins were transferred onto a 
nitrocellulose membrane (Whatman, Florham park, NJ) and blocked with 5% milk-TBST 
(Tris buffered saline Tween-20) (20 mM Tris-HCl, pH 7.6, 137 mM NaCl, 0.1% Tween-
20) solution. The membrane was incubated with primary antibodies (anti-FVT1, diluted 2  
µg/ml) for 1hr at room temperature and washed with TBST solution before being probed 
with a secondary anti–fluorescein antibody (ECF kit) for 1 h.  The protein bands were 
visualized by incubating the membrane with the ECF substrate for 30 min and imaged 
using FLA-3000 imager (Fujifilm, Stamford, CT).   
 
5.3.8 Synthesis of 3-keto dihydroceramide internal standard 
 For the synthesis of C16 and C24 3-keto dihydroceramide internal standards, 2 
mg of substrate (C16 and C24 dihydroceramides respectively) were dissolved in 0.2 ml of 
dry benzene. The oxidation reaction was by the addition of 0.2 ml (6.5 mg/ml) of CrO3 in 
dry pyridine solution and the mixture was kept at room temperature for 2 hr with 
occasional shaking. To minimize the presence of moisture, the tube was purged with 
argon. The reaction was terminated by adding it to a cold solution of 5N HCl (0.6 ml), ice 
(0.6 ml) and chloroform (1 ml) and chilled for 10 min. After shaking, the chloroform 
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layer was removed and the aqueous layer was re-extracted twice with 0.5 ml chloroform 
and extract was added to the original chloroform layer. Combined extracts were washed 
with 1 ml of water and dried over anhydrous sodium sulphate. The completion of the 
reaction was confirmed by TLC using Silica gel 60 plates (Merck). The substrate and 
products were resolved using chloroform: methanol (50:1) mobile phase and visualized 
by staining the plates with primuline (Sigma). The standards were also validated by the 
infusion method using ESI-MS/MS. 
 
5.3.9 LC-ESI-MS/MS analysis of 3-keto dihydroceramides 
 Cells were grown in culture as described above and extracted for mass 
spectrometry analysis as previously described  [208]. The sphingolipid extracts were 
resolved by reverse phase HPLC using a discovery C18 column (supelco-Sigma Aldrich) 
using a gradient mobile phase containing solutions A (99:1  methanol:formic acid, 5 mM 
ammonium formate) and B (58:41:1 methanol:water:formic aicid, 5 mM ammonium 
formate). The 3-keto dihydrocermides were detected using  triple quadrupole mass 





5.4.1 Identification of human of 3-ketosphinganine reductase (3KSR) 
 
 To identify the open reading frame (orf) encoding the human 3KSR a blast search 







Fig 5.1 Sequence alignment comparison of human and yeast 3-Ketosphinganine 
peptide. The peptide sequence of yeast 3-Ketosphinganine reductase (NP_009824.1)  and 
human follicular lymphoma variant translocation 1 (NP_002026.1) were obtained from 
NCBI database and aligned using the T-coffee algorithm [224].  The sequence region 











The search identified follicular lymphoma variant translocation 1 (FVT1), sepiapterin 
reductase (SPR) and estradiol 17 beta-dehydrogenase 8 (17-beta-HSD 8) as the closest 
homologs with 24 %, 22 % and 21 % sequence identity respectively with the yeast 
mRNA. Since FVT1 had the sequence homology along the entire length of the yeast 
3KSR peptide (Fig 5.1) and possessed the catalytic triad (Fig 5.1 residues highlighted by 
a red outline)  required for the catalytic activity of short chain reductases [225], it was 
selected for experimental evaluation.   
 
5.4.2 Development of HPLC based assay for 3-ketosphinganine reductase  
In order to verify the activity of 3-ketosphinganine reductase in cells, an enzyme assay 
adapted for HPLC analysis was developed with modification to a previously reported 
protocol employing radio isotopes [219].  This protocol, as described in the methods 
section,  is based on the principle of fluorescent derivatization of long chain bases (i.e So, 
Sa etc) with o-phthalaldehyde (OPA). The fluorescent conjugates are well resolved by 
reverse phase HPLC and detected by florescence [223]. HPLC analysis of internal 
standards showed that the mixture of substrate 3-ketosphinganine (C18 3-ketoSa) and 
C20 sphingosine (C20 So) produce a single peak (Fig 5.2 B), while a combination of 
product standard (C18 Sa) and C20 So produce two distinct peaks (Fig 5.2 C). The 
absence of a peak for 3-KetoSa was confirmed by analysis of the substrate alone (Fig 5.2 
A) (except OPA fluorescence in the void volume).  
To validate the separation of product and substrate from assay extracts, in vitro 





Fig 5.2 HPLC analysis of enzyme assay. HPLC analysis was performed for long chain 
bases internal standards and 3-ketosphinganine assay extracts following derivatization of 
the long chain bases with OPA and the products were resolved by reverse phase HPLC 
using a C18 pack column as previously described [223]. The panel depicts 
chromatograms for internal standards A) C18 3-keto sphinganine (3-ketoSa), B) 3-ketoSa 
+ C20 sphingosine (C20 So) and C) C18 sphinganine (C18 Sa) and C20 So. The elution 
of internal standards were compared to extract of invitro enzyme assay that was 
conducted with equal quantities of substrate and either D) 10 µg protein or E) 100 µg 
protein as total cell lysate. Prior to extraction the assay samples with spiked with equal 
amounts of C20 So as internal standards. F) depicts the chromatogram for C18 Sa + C20 






10 µg, 50 µg or 100 µg protein equivalent cell lysate. Before extraction of the assay 
mixture all samples were spiked with 1 nmol of C20 So. Analysis of the assay extracts  
show that with increase in protein concentration higher proportion of C18 Sa (product) 
(Fig 5.2 D, E) was detected as compared to constant amounts of internal standards. The 
peaks for the product and show a elution profile similar to C18 Sa and C20 So standards 
(Fig 5.2 F) 
 
5.4.3 Analysis of 3KSR activity in Hela cells over expressing FVT1 
To assess if FVT1 possess 3KSR activity, the pEGFP control vector or FVT1 cloned into 
pEGFP were transiently transfected into Hela cells for 48 hr in 6-well plates. After the 
verification of the transfection efficiency by fluorescence microscopy, the cells were 
collected by scraping and invitro enzyme activity assays were performed. The LCBs from 
the assay mixture were extracted and analyzed by reverse phase HPLC.  Hela cells 
transfected with pEGFP-FVT1 displayed 663 + 140 pmol/mg protein/min activity for 
3KSR (Fig 5.3 E), as compared to 372 + 75 pmol/mg protein/min for empty vector 
transfected Hela cells (p< 0.05, n= 4) (Fig 5.3 E). The representative chromatograph for 
the enzyme assays (Fig 5.3 A,B) closely align with the peaks for standards. This study 
suggested that ectopic expression of FVT1 resulted in elevated 3KSR activity.  
 
5.4.4 Measurement of 3KSR activity in E.coli transformed with FVT1  
Because Hela cells possess background 3KSR, the activity of the peptide produced by 
FVT1 was verified by ectopic expression in E.coli following the induction of protein 




Fig 5.3 Analysis of the 3-ketosphinganine reductase activity in Hela cell transfected 
with FVT1. Hela cells were transfected with FVT1 cloned into the pEGFP or the vector 
alone in 6-well plates. The cells were harvested 48 hr after transfected and in vitro 
enzyme activity assay was performed  as described in the methods section and analyzed 
by reverse phase HPLC.  The representative chromatograph for A) control vector, B) 
FVT1transfected Hela cells were compared with chromatographic peaks for C) C18 Sa 
and D) C20 So standards.  E) depicts the graphical representation of activity in A and B 
in pmole/mg protein/min. The significance as indicated by an asterisk was determined by 
a t-test at p-value < 0.05 
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the supernatant was used for a 3KSR in vitro enzyme activity assay as described in the 
methods section and the LCB were extracted and analyzed by reverse phase HPLC.   
Results showed that E.coli transformed with FVT1 produced 754 + 117 pmol/mg 
protein/min C18 Sa (Fig 5.4 B, E) as compared to 11 + 7 pmol/mg protein/min in E.coli 
transformed with the empty vector (Fig 5.4 A, E) (p < 0.001, n = 4). E.coli cells 
expressing a mutant FVT1 peptide produce 17 + 12 pmol/mg protein/min C18 Sa (Fig 5.4 
C, E), which further verifies the finding that wildtype FVT1 transcript possess 3KSR 
activity. These findings confirm that FVT1 possesses 3KSR activity. This conclusion has 
been confirmed by somewhat later study [148]. 
 
During this period a study reported that FOXC1 was a putative transcription regulator of 
3KSR [226] and showed that Hela cells lack FOXC1 due to deletion of the genomic 
sequence [222]. Therefore, in the remaining chapter we use the Hela cell model to 
investigate the consequences of FOXC1 deletion on the activity of 3KSR and the 
composition of its metabolites.  
 
5.4.5 Composition of 3-ketosphinganine intermediates in Hela and Hek SPT1/2 cells 
 Because reports showed that FOXC1 was a putative transcription regulator of 
FVT1 (3KSR) [226] and Hela cells had a defective FOXC1 [222] the sphingolipids of 
Hela and Hek SPT1/2 cells were compared. Both cell lines were grown in culture and 
their sphingolipids were extracted and analyzed by liquid chromatography electrospray 




Fig 5.4 Analysis of the 3-ketosphinganine reductase activity in E.Coli  transformed 
with FVT1. Ecoli cells were transformed with FVT1, mutant FVT or the control vector, 
and the peptide production was induced for 5 hr. The assay was conducted with 10 min as 
described in the methods section and the product was analyzed by reverse phase HPLC. 
The representative chromatograph for A) control vector, B) FVT1, C) FVT1-mut were 
compared to peaks for D) standard C18 Sa and C20 So.  E) depicts the graphical 
representation of activity in A, B and C in pmole/mg protein/min. The significance as 








revealed that Hela cells had 4.1 + 0.9 pmol C16-3Keto DHCer/mg protein and 1.3 + 0.2 
pmol C18-3Keto DHCer/mg protein (Fig 5.5) versus undetectable C16-3Keto DHCer and 
0.07 + 0.04 pmol C18-3Keto DHCer/mg protein in Hek SPT1/2 cells (Fig 5.5) (p< 0.05, 
n=3). 3-keto DHCer with longer chain length fatty acids were below the limit of detection 
of the instrument. In comparison, no significant amounts of 3-ketosphinganine was 
detected in either cell lines. These findings suggest that the accumulating 3-keto 
sphinganine in Hela cells is rapidly N-acylated to 3-keto dihydroceramide due to a 
defective FOXC1 gene.  
 
5.4.6 Verification of FOXC1 expression in Hela cells 
To ascertain if the Hela cells used for sphingolipid profiling had its FOXC1 gene deleted 
as previously reported [222], genomics DNA from Hela and HekSPT1/2 cells were 
isolated. The FOXC1 orf was amplified by a PCR reaction using the primers representing 
the start and stop codons, as the gene doesn‟t contain introns [222].  The products of the 
PCR reaction were resolved by agarose gel, which revealed a prominent band at 1662 bp 
for Hek SPT1/2 cells (Fig 5.6). In contrast, no band was observed in Hela cells (Fig 5.6). 
These finding suggest that the accumulation of 3-keto dihydrocermides in Hela cells may 
possibly be regulated by the expression of FOXC1 in cells. 
 
5.4.7 Expression of 3KSR in different cell lines 
Because a report suggested that FOXC1 was a putative transcription regulator of 
FVT1 [226] and Hela cells displayed greater accumulation of 3-keto dihydroceramide 







Fig 5.5 LC-ESI-MS/MS analysis of 3-ketodihydrocermide in HekSPT1/2 and Hela 
cells. Both the cells were grown in culture medium and the cells were collected by 
scraping in PBS. Sphingolipids were extracted and analyzed by LC-ESI-MS/MS using a 
previous protocol [208].  The chart displays the fatty acid distribution of in 3-
ketodihydroceramide in pmol/ mg protein for subspecies indicated in the color chart.  The 
















Fig 5.6 PCR amplification of FOXC1 orf in HekSPT1/2 and Hela cells. Genomic 
DNA from HekSPT1/2 and Hela cells was isolated using a genomic DNA isolation kit. 
Equal amounts of DNA template were amplified using PCR reaction and the product was 












HekSPT1/2 cells. The cells were grown in culture and the western blot analysis was 
performed on the whole cell lysates. Comparison of protein from the cell lines revealed  
 
To verify the effect of the low expression of FVT1 peptide in Hela cells the 
activity of 3KSR in the Hela and Hek SPT1/2 cells was determined by an invitro enzyme 
activity assay. The HPLC analysis of the activity assay indicated that Hela cells had 
activity of 0.27 pmol/µg/min for 3KSR as compared to 0.61 pmol/µg/min activity in Hek 
SPT1/2 cells. These finding suggest that the lack of FOXC1 results in lower expression 
and activity of 3KSR in Hela cells. 
 
5.4.8 Analysis of FVT1 gene expression in the NCI60 cell panel 
 To compare the expression of 3KSR (FVT1) between a panel of cell lines 
including, Hela the mRNA abundance for FVT1 in the NCI60 cell panel was compared 
using the cell lines using the BioGPS browser [227]. The comparative analysis revealed 
that Hela cells (Fig 5.8) have among the lowest expression compared to other cell lines.  
 
5.4.9 Evaluation of 3KSR enzyme activity in Hela cells after FOXC1 transfection 
In order to rescue 3KSR activity and reverse the accumulation of 3-keto 
dihydroceramide in Hela cells, the human FOXC1 ORF was cloned as described in the 
methods section. Hela cells were grown in100 mm dishes and transfected with control 
(pcDNA) or  FOXC1 vector for 48 hr, and subsequently incubated with 30 µM 3-











Fig 5.7 Comparison of 3KSR peptide in cell line. Whole cell lysates of Hek, 
HekSPT1/2, Hela and Hela-3KSR cells were prepared and equal amounts (15 μg) of 
protein were separated by an SDS-PAGE gel.  The anti-FVT1 antibody was used to 
detect 3KSR peptide, while the detection of GAPDH with an anti-GAPDH antibody was 




















Fig 5.8 Global analysis of FVT1 expression in NCI60 cell panel. To compare the 
expression of FVT1 between a panel of cancer cell lines including Hela cell, a search was 





sphingolipids were extracted and analyzed by LC-ESI-MS/MS as previously described 
[211]. Hela cells transfected with FOXC1 had 2.64 + 1.6 pmol total 3 keto- 
dihydroceramide /mg protein as compared to control transfected Hela cells, 2.3 + 1.2 
pmol total 3 keto- dihydroceramide /mg protein. These results suggest that transfection of 
FOXC1 was unable to cause a significant increase in 3KSR activity in Hela cells.  
 
5.5 Conclusion 
This study reports application of bioinformatics analysis in the successful 
identification of 3KSR. In vitro enzyme activity assay in Hela and Ecoli cells verified the 
3KSR enzyme activity of human FVT1 ORF activity of human FVT1. Furthermore, 
using the knowledge of transcription factor binding studies and the Hela cell model the 
accumulation of N-acyl product of 3-ketosphinganine intermediate was detected. 
However the restoration of FOXC1 expression in Hela cells was unable to rescue 3KSR 
activity. This study demonstrates the advantage of combining sequence analysis with 












CHARACTERIZATION OF MUTANT SERINE 
PALMITOYLTRANSFERASE 1 IN LY-B CELLS AND ITS PARTIAL 
STABILIZATION, WITHOUT DETECTABLE ENZYMATIC 




 Sphingoid base biosynthesis is initiated by serine palmitoyltransferase (SPT; 
EC2.3.1.50) [228], an activity that is essential for cells in culture unless the medium is 
supplemented with sphingolipids [229].  SPT is comprised of two [228], and possibly 
more subunits  [147, 230], and homozygous deletion of two subunits (Sptlc1 and Sptlc2, 
also known as LCB1/LCB2 or SPT1/SPT2) in mice is embryonic lethal [231].  Because 
the mammalian SPT is a membrane protein, its crystallization has been a challenge. 
Bioinformatics based homology modelling is a possible approach to model SPT structure, 
since it is related to previously crystallized class of pyridoxal 5-phosphate dependent 
enzymes. This technique has been previously applied to study the impact of amino acid 
substitutions in SPT during hereditary sensory neuropathy type 1 (HSN1) [232, 233].  
 Sptlc1 subunit of LY-B cells lack SPT activity due to a mutation [229], and 
therefore they have been used as models for studies of de novo sphingolipid biosynthesis 
and the functions of sphingolipids [229]. However the cause of the dysfunctional SPT 
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activity in these cells is unclear. During this study sequencing of the SPTLC1 mRNA 
from LY-B cells identified the mutation as a guanine to adenine change at nucleotide 
738, causing a G246R transformation. Western blots revealed low expression of the 
mutant SPT1 peptide, but activity was not detectable by mass spectrometric analysis of 
[
13
C]-palmitate incorporation into sphinganine, sphingosine, 1-deoxysphinganine, or 1-
desoxymethylsphinganine.  Treatment of LY-B cells with chemical chaperones (DMSO 
or glycerol) increased the amounts of mutant SPT1 as well as SPT2, but SPT activity was 
not restored.  This study has established that G246R mutation in hamster SPT1 results in 





Chinese hamster ovary (CHO) derived lines LY-B and LY-B/cLCB1 (which are stably 
transfected with the Chinese hamster LCB1 cDNA to restore SPT activity) were available 
from previous studies [229]. Ham‟s F12 medium was from Gibco (Carlsbad, CA) and 
fetal bovine serum was obtained from Hyclone (Logan, UT). The sources for the 
antibodies were BD Biosciences (San Jose, CA) for the anti-LCB1 monoclonal antibody, 
Cayman (Ann Arbor, MI) for the anti-SPT2 monoclonal antibody, Sigma (St. Louis, MO) 
for the anti-beta actin and anti-HA antibodies, Ambion (Austin, TX) for the anti-GAPDH 
antibody, and David Uhlinger (Johnson & Johnson Pharmaceutical Research & 





was purchased from GE healthcare 
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(Piscataway, NJ). Mass spectrometry internal standards were obtained from Avanti Polar 
Lipids (Alabaster, AL) and [U-
13
C]- palmitic acid was purchased from Cambridge 
Isotope (Andover, MA).  Fumonisin B1 (FB1) was obtained from Biomol (Plymouth 
Meeting, PA).  All other reagents and solvents were of high quality.  
 
 
6.2.2 Cell culture and treatments 
LY-B and LY-B/LCB1 cells were cultured in Ham‟s F12 medium containing 10% 
fetal bovine serum, penicillin G (100 U/ml) and streptomycin sulfate (100 μg/ml) in 5% 
CO2 at 37 °C.   During stable isotope labeling studies, the media was supplemented with 
0.1 mM [U-
13
C]-palmitic acid complexed with equimolar fatty acid free BSA 
(Calbiochem, Gibbstown, NJ). After 12 or 24 h, depending on the experiment, the 
incorporation of stable isotope into sphingolipids was measured by liquid 
chromatography, electrospray ionization tandem mass spectrometry (LC ESI-MS/MS) as 
previously described [235] except as noted below.   
 To analyze whether LY-B and LY-B/LCB1 cells produce both the “typical” 
sphingoid bases (i.e., sphinganine and sphingosine) and the recently discovered 
“atypical” sphingoid bases (1-deosysphinganine and 1-desoxymethylsphinganine) [11, 
236], 25 M FB1 was added to the cells one hour before addition of the 0.1 mM [U-
13
C]-
palmitic acid-BSA complex (and the FB1 was included in the medium for the full 24 h 
incubation) to cause the sphingoid bases to accumulate [236].   
 For chemical chaperone treatment of LY-B cells, the cells were grown to 
approximately 50% confluence and changed to media supplemented with different 
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concentrations of DMSO (up to 3%) or glycerol (up to 1 M) for 24 h. To determine how 
this affected SPT amount, the SPT1 and SPT2 peptides were visualized by western 
blotting as described in 2.3. GAPDH was used as the protein loading control because 
DMSO and glycerol have been noted to influence the expression of actin [237-239].  To 
determine how SPT activity was affected, the cells were incubated for an 12 h in the 
same medium supplemented with 0.1 mM [U-
13
C]-palmitic acid-BSA complex then the 
[
13
C]-labeled sphingolipids were determined by LC ESI-MS/MS. 
 
6.2.3 Cloning and sequencing of SPT1 from LY-B cells 
 Total RNA was extracted from LY-B cells by the Absolutely RNA Miniprep Kit 
(Qiagen, Valencia, CA) and reverse transcribed to cDNA using the cDNA Synthesis 
System Kit (TaKaRa, Mountain View, CA). PCR was performed to amplify the SPT1 
transcript using primers (5‟- atggcgatggcggcggagca and 3‟- ctacagcagcacagcctgggca), 
which represents the start and stop codon for hamster SPT1 open reading frame. The 
amplified PCR transcript was ligated into pUC18 cloning vector and restriction digested 
with EcoRI to determine the clones with the correct inserts. 15 selected clones were 
sequenced (Nevada genomics center, Reno, NV) and compared to wildtype CHO SPT1 
mRNA by multiple sequence alignment using T-coffee [224]. 
 
 
6.2.4 Western blotting 
 After the experiment the cells were scraped from the dishes into PBS solution 
containing Complete Mini protease inhibitor cocktail (Roche Diagnostics, Indianapolis, 
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IN) and lysed by sonication. The total cell lysate was incubated with Benzonase Nuclease  
(Novagen, Madison, WI) for DNA cleavage for 30 min at room temperature, following 
which equal amounts of protein (40 μg) were separated by 12% SDS-PAGE (Pierce, 
Rockford, IL) minigel (10 well) in Tris-HEPES-SDS (100mM Tris, 100mM HEPES, pH 8.0, 
3mM SDS) running buffer and electrophoresed at 160 volts. The separated proteins were 
transferred onto a nitrocellulose membrane (Whatman, Florham park, NJ) and blocked 
with 5% milk-TBST (Tris buffered saline Tween-20) (20 mM Tris-HCl, pH 7.6, 137 mM 
NaCl, 0.1% Tween-20) solution. The membrane was incubated with primary antibodies 
(anti-LCB1, diluted 1:2000; Anti-SPT1, diluted 1:3000; anti-SPT2, diluted 1:1000) 
overnight at 4
o 
C and washed with TBST solution before being probed with a secondary 
anti–fluorescein antibody (ECF kit) for 1 h.  The protein bands were visualized by 
incubating the membrane with the ECF substrate for 30 min and imaged using FLA-3000 
imager (Fujifilm, Stamford, CT).  Pixel density was measured using Multi Gauge 
(Fujifilm) image analysis software. Statistical significance was defined at a p-value of 
0.05 using the Kruskal-Wallis rank sum test in R v2.61 (www.r-project.org). 
 
6.2.5  LC ESI-MS/MS analysis of sphingolipids 
 The sphingolipids were analyzed in positive ionization mode by LC ESI-MS/MS 
[235] using ABI 3000 triple quadrupole and ABI 4000 quadrupole-linear ion trap mass 
spectrometers (Applied Biosystems, Foster City, CA).  Since the major fragmentation 
products of ceramides and ceramide monohexosides (e.g., ions with m/z 264.4 for 
sphingosine and m/z 266.4 for sphinganine) retain the carbon atoms originally derived 




palmitate into the sphingoid base backbones were determined by adding 16 mass units to 
the precursor-product pairs for species labeled in only the sphingoid base backbone, and 
by adding 32 mass units to the precursor ion and 16 to the product for compounds labeled 
in both the fatty acid and the sphingoid base.  Since these product ions are of very low 
abundance from sphingomyelins [235], the incorporation of [U-
13
C]-palmitate into the 
sphingoid base backbones of SM was determined by treatment of an aliquot of the lipid 
extract with the phospholipase D from Streptomyces chromofuscus (Sigma) to produce 
ceramide 1-phosphates phosphates [240, 241], which do provide definitive information 
about [
13
C] labeling of the sphingoid base backbone [211, 235].  This treatment was 
conducted by incubating dried lipid extracts with 50 units of the enzyme suspended in 0.1 
ml of 100 mM Tris HCl, pH 8.0, and 3 mM decylglucopyranoside (Sigma), at 37
o 
C for 
30 min.  The reaction was dried by speedvac and analyzed by LC ESI-MS/MS.  
 Analysis of the biosynthesis of sphinganine (So), sphingosine (Sa) and the 
“atypical” sphingoid bases (1-deosysphinganine, 1-deoxy-Sa, and 1-
desoxymethylsphinganine, 1-desoxymethyl-Sa) [11, 236] by cells incubated [U-
13
C]-
palmitate and 25 M FB1 was conducted by LC ESI-MS/MS using multiple reaction 
monitoring with Q1 and Q3 set to pass the following precursor and product ions in 







C]-1-deoxy-Sa), and 288.3/270.3 ([
13
C]-1-desoxymethyl-Sa).  The LC conditions 
were the same as described previously [236], i.e. using a reverse phase LC column 
(Supelco 2.1 x 50 mm Discovery C18 column, Sigma, St. Louis, MO) and a binary 
solvent system at a flow rate of 0.6 mL/min delivered by a Shimadzu LC-10 AD VP 
binary pump; the binary system began with equilibration of the column with a solvent 
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mixture of 60% mobile phase A (CH3OH/H2O/HCOOH, 58/41/1, v/v/v, with 5 mM 
ammonium formate) and 40% mobile phase B (CH3OH/HCOOH, 99/1, v/v,  with 5 mM 
ammonium formate), sample injection (typically in 50 µL of the same mixture), elution 
with this mixture for 1.3 min followed by a linear gradient to 100% B over 2.8 min (then 
a column wash with 100% B for 0.5 min followed by a wash and re-equilibration with the 
original A/B mixture before the next run). 
 
6.2.6 Homology modelling of mutant SPT1 
 Homology modelling was performed to predict the structure of the mutant SPT1 
by comparing it with two crystallised POAS enzymes [233], including the newly 
crystallized serine palmitoyltransferase from the bacterium Sphingomonas paucimobilis 
(PDB ID: 2JG2) [232]. In the first step, two crystal structures were selected (PDB ID: 
2JG2 and 1FC4) as templates by a blast search of the PDB database using the query SPT1 
peptide, because they possess high sequence identity (30 %). The sequences of the 
template and mutant SPT1 protein were aligned using T-coffee [224] and refined 
manually into a PIR format alignment file. The homology model was generated by 
Modeller v6.1 [242] using the PDB template, alignment file and instruction files, and 




6.3.1 Analysis of the gene sequence for mutant SPT1 in LY-B cells 
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 Sequencing of the mutated SPT1 from LY-B cells revealed a guanine to adenine 
mutation at nucleotide residue 738, which would result in the substitution of Arg for 
Gly246, which is conserved across numerous species (hamster, mouse, human and S. 
cerviceae), as shown in Fig. 6.1A.  Homology modeling (Fig. 6.1B) predicts that this  
transformation places Arg246 in the vicinity of the non-polar residues Phe, Gly, Val and 
Leu, which would be likely to interfere with the correct folding of SPT1. 
 
6.3.2 Analysis of mutant SPT1 polypeptide in LY-B cells 
 
 Previous studies have not detected an SPT1 peptide in LY-B cells by Western 
blotting [229], however, a very faint band is discernable when larger amounts of protein 
(40 g) are examined using two antibodies (anti-LCB1 and anti-SPT1) (Fig. 6.2A and C) 
but not using an antibody to another polypeptide epitope not found in the cells (HA) (Fig. 
6.2B).  Also shown is the staining of SPT1 in LY-B/cLCB1 cells, which have been stably 






Fig. 6.1 Sequence comparison and homology model of the SPT1 mutant protein of 
LY-B cells. (A) Protein sequences of SPT1 were compared from LY-B cells, CHO, 
human, mouse and S. cerviceae using T-coffee. The point mutation G246R in LY-B cells 
is indicated by an asterisk. (B) This homology model for mutant SPT1 from LY-B cells 
was prepared using Modeller v6.1. The illustrated figure shows the G246R mutation 
(indicated in a ball and stick representation) to be located in a pocket of hydrophobic 








6.3.3 Analysis of mutant SPT activities in LY-B cells 
 To ascertain whether this small amount of mutant SPT1 afforded detectable de 
novo sphingolipid biosynthesis, cells were incubated with [
13
C]-palmitic acid and 
analyzed for incorporation of [
13
C] into the sphingoid base backbone (with free sphingoid 
bases in Fig. 6.3A and complex sphingolipids in Fig. 6B-D); LY-B/cLCB1 cells were 
used as a positive control because they have SPT activities comparable to wild-type CHO 
cells [229].  When all of the subspecies are summed, the amounts of backbone [
13
C]-
labeled sphingolipids in the LY-B/cLCB1 cells at 6 h were 62 + 0.3 pmol Cer/mg protein, 
54 + 0.8 pmol HexCer/mg protein and 300 + 14 pmol SM/mg protein, for a total of ~416 
pmol/mg protein; for LY-B cells, the amounts were below the limits of detection for Cer 
and HexCer (~ 0.1 pmol/mg protein) and very low for SM (5.5 + 16 pmol SM/mg 
protein) which, based on the high noise in the signal (reflected in the high SD), might be 
due to other compounds with similar ionization characteristics.  Thus, even counting the 
possibility that this represents SM, the maximum amount of labeled backbone 
sphingolipids in the LY-B cells would only ~1% that in LY-B/cLCB1 cells.  
As has been shown before [229], although LY-B cells are defective in 
sphingolipid biosynthesis de novo, they contain appreciable amounts of sphingolipids if 
grown in medium that contains sphingolipids (e.g., from serum).  In these studies, the 
pmol of unlabelled sphingolipids/mg protein for LY-B vs LY-B/cLCB1 cells (measured 
by LC ESI-MS/MS) were, respectively: 140 + 18 vs 1073 + 17 for Cer; 122 + 7 vs 447 + 







Fig. 6.2 Western blots of SPT1 in LY-B and LY-B/cLCB1 cells. Whole cell lysates of 
LY-B and LY-B/cLCB1 cells were prepared and equal amounts (40 μg) of protein were 
separated by an SDS-PAGE gel. Replicate membranes were probed with (A) a 
commercial LCB1 antibody; (B) an anti-HA antibody as a negative control, and (C) an 
independent anti-SPT1 polyclonal antibody. The detection of -actin with an anti- -actin 





Fig. 6.3. Comparison of de novo sphingolipid biosynthesis in LY-B and LY-B/cLCB1 cells. LY-B 
and LY-B/cLCB1 cells were incubated with 0.1 mM [13C]-palmitic acid for 0, 3 and 6 h and the 
sphingolipids labeled in the sphingoid base alone (BASE) plus the sphingoid base and fatty acid 
(DUAL) were measured by LC ESI-MS/MS. The black bars represent the sphingolipids in LY-
B/cLCB1 cells while the white bars indicate the LY-B cells. (A) [13C]-labeled long-chain bases (LCB) 
sphingosine, So; sphinganine, Sa; sphingosine 1-phosphate, SoP; and sphinganine 1-phosphate, 
SaP. (B-D) provide the sum of the label in the BASE and DUAL subspecies of ceramide, Cer,  
monohexosylceramides, HexCer, and sphingomyelins, SM, based on variation in the chain length 









   
 97 
 As another way to assess sphingoid base biosynthesis, the cells were incubated 
with FB1 to allow accumulation of the [
13
C]-labeled sphingoid bases, which are otherwise 
rapidly N-acylated to complex sphingolipids, and thus less easily tracked.  These results 
are shown in Fig. 5.4 as the relative ion yields for the precursor/product pairs as they 
elute from the reverse phase column.  Production of [
13





C]-1-deoxy-Sa (Fig. 6.4B) and [
13
C]-1-desoxy-methyl-Sa (Fig 6.4D) were 
readily detected with the LY-B/cLCB1 cells, but the signal was but not above 
background for the LY-B cells, which further confirms the conclusion from Fig. 6.3 that 
the LY-B cells do not synthesize detectable amounts of sphingoid bases de novo.  The 
appearance of [
13
C]-sphingosine in LY-B/cLCB1 cells was somewhat surprising because 
desaturation of sphinganine is thought to occur only after N-acylation [244], but it is 
possible that this concentration of FB1 did not completely block [
13
C]-Cer biosynthesis 
and this  [
13
C]-sphingosine arose from turnover.  
 
6.3.4 Partial stabilization of mutant SPT in LY-B cells 
 Some misfolded proteins can be stabilized by so-called chemical chaperones such 
as DMSO and glycerol [245-247].  When LY-B cells were treated for 24 h with DMSO 
or glycerol at concentrations where they have previously been effective, there were 
noticeable increases in both SPT1 and SPT2 by Western blotting (Fig. 6.5, upper), with 
the average increases in five experiments being between 2- and 3-fold (Fig. 6.5, lower).  
Lower concentrations had no effect, and higher were toxic (data not shown).  In case 
these treatments also resulted in restoration of SPT activity, the incorporaton of [
13
C]- 
palmitate into sphingolipids was measured after LY-B cells had been treated with either 
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3% DMSO or 1 M glycerol for 24 h (the [
13
C]-palmitate was added to the same medium 
and the cells were incubated for 12 h before extraction for sphingolipid analysis by LC 
ESI-MS/MS).   As noted earlier, the ion yields for the 
13
C-labelled, we would estimate 
that the amounts were 2.0 + 0.47 pmol/mg protein for the LY-B cells alone , 1.6 + 0.2  
pmol/mg protein for the LY- cells incubated with 3% DMSO and 2.33 + 1.15 pmol/mg 
protein for LY-B cells in 1M glycerol.Therefore,  there was no evidence that the small 
amounts of SPT1 detected upon treatment of the cells with these chemical chaperones 









Fig. 6.4. Relative amounts of typical and atypical [
13
C]-labelled sphingoid bases 
produced by LY-B and LY-B/cLCB1 cells upon co-treatment with FB1.  Shown are 
the relative ion intensities of the shown precursor/product pairs in the LC ESI-MS/MS 
eluates.  The LC retention times for these species matched that of standards for these 
compounds (not shown).  The samples for these analyses were obtained by incubating 
LY-B and LY-B/cLCB1 cells with 0.1 mM [
13
C]-palmitic acid and 25 μM FB1 for 24 h; 





Fig. 6.5. Elevation of the amounts of SPT1 and SPT2 in LY-B cells treated with 
chemical chaperones. LY-B cell were treated with DMSO (left panels) or glycerol (right 
panels) at the shown concentrations for 24 h then analyzed by Western blotting (upper 
panels), with GAPDH as the loading control. The lower panels are the relative 
differences in protein amounts as estimated from the pixel densities of the bands from 
five independent Western blots (bottom panels), with the standard error indicated by the 
bars. Ratios that were significantly different from the control (no treatment, 0) at P < 








Structure bioinformatics and sequence alignment provided valuable hypothesis 
that resulted in the sequencing and identification of nucleotide substitution in SPT1 
transcript (G246R) from LY-B cells. These results are consistent with the fact that LY-B 
cells were produced using ethyl methanesulfonate [229], a mutagen that causes the 
random replacement of guanine(s) with adenine. Furthermore, the very low amounts of 
detectable mutant SPT1 polypeptide is consistent with the translated protein being 
unstable, which would be predicted upon localization of a positively charged Arg in a 
hydrophobic region of the enzyme, as suggested by the homology model [248].  It was 
worthwhile, nonetheless, to test for possible SPT activity given the recent discovery that 
SPT is able to produce not only sphinganine (and downstream sphingosine) but also the 
atypical sphingoid bases, 1-deoxysphinganine (from alanine) and 1-
desoxymethylsphinganine (from glycine) [236]; furthermore, it has been suggested that 
these are elevated in the mutated SPTLC1 found in human sensory neuropathy type 1 
(HSN1) [11].  However, the LY-B cells produced no detectable sphingoid bases of any of 
these types.   
 Therefore, for most studies, the presence of small amounts of mutant SPT1 
polypeptide is not likely to interfere with the investigation.  Its presence should be kept in 
mind, nonetheless, during investigations where the residual protein might become 
stabilized and complicate interpretation of studies of protein-protein interactions or other 







Summary and future directions 
 
 
Sphingolipids have important biological roles, and changes in their amounts have 
been linked to pathogenesis in wide range of diseases including cancers, where they 
promote cell adhesion, migration, proliferation and metastasis. However, it is challenge 
to characterize variations in all sphingolipid species due to their high structural diversity. 
The integration of different omics approaches such as transcriptomic and metabolic 
measurements provides new avenues to identify novel sphingolipid alterations. This 
dissertation aims to develop new and use existing bioinformatics techniques to 
investigate factors influencing sphingolipid biosynthesis.   
 
  To facilitate the integrative analysis of gene expression and sphingolipid amounts, 
updated pathway maps were prepared using an open access visualization tool, Pathvisio 
v1.1. The datasets were formatted using Perl scripts and visualized with the aid of color 
coded pathway diagrams. Comparative analysis of transcriptomics and sphingolipid 
alterations from experimental studies and published literature revealed 72.8 % correlation 
between mRNA and sphingolipid differences (p-value < 0.0001 by the Fisher‟s exact 
test). Conversely, pathway analysis of gene expression has also directed attention towards 
novel sphingolipid alteration, such as the elevation of phyto-sphingolipids and d16:1 Cer 
in MCF7 and MDA-MB-231 cells respectively. Thus comparison of gene expression and 
metabolite amounts using pathway diagrams has the potential to provide mechanistic 
 103 
insight related to differential sphingolipid composition and also predict novel subspecies 
present in cancer cells and tissues. This approach has great potential to help the discovery 
of glycosphingolipids biomarkers in cancers and other disorders with specific knowledge 
of glycan head group and sphingoid base backbone. 
 
 As more dataset become available, visual analysis of gene expression pathway 
diagrams can be cumbersome. A solution to this challenge might be the development of 
mathematical algorithms for the prediction of putative branches of altered sphingolipids. 
Some of the potential approaches likely to provide such analysis my involve bayesian 
network and graph theory. Conversely, with wider availability of lipidomic datasets it 
could be possible to develop machine learning test to predict metabolite composition 
based on the gene expression signatures. These computational tools may be highly 
complementary to recent undertakings by Lipidmaps consortium to develop mass 
spectrometric methods for the quantitation of higher order glycosphingolipids.   
 
During the preparation of the maps it was noted that a number of transcripts 
encoding sphingolipid biosynthetic enzymes were undiscovered. The human transcript 
for one such enzyme, 3-keto sphinganine reductase was identified and validated during 
this dissertation using molecular cloning and in vitro enzyme activity assay. Furthermore, 
mass spectrometry analysis of Hela cells which have defective FOXC1, a putative 
transcription regulator of FVT1 showed greater accumulation of N-acyl 3-
ketosphinganine. However the transfection of FOXC1 into Hela cells was unable to alter 
3KSR expression and reduce N-acyl 3-ketosphinganine amounts. Though this didn‟t 
show the intended reversal with the gene transfection it is likely that additional subunits 
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of the transcription factor complex and post translational modification through protein 
kinases may play a role in regulation of FOXC1 activity.   
The last study in this dissertation employs structure bioinformatics (homology 
modeling) and multiple sequence alignment to characterize SPT protein in LY-B cells 
that lack de novo sphingolipid biosynthesis. This in silico study identified a point 
mutation potentially resulting in the misfolding of SPT and loss of its enzyme activity. 
Treatment of LY-B cells with chemical chaperone partially stabilized SPT, without 
rescuing its activity. A potential application of structural modeling could be for the 
analysis of genomics alteration detected within genes in genome wide association studies 
and SNP‟s.   
 
 Thus studies in this dissertation demonstrate that the gene expression pathway 
maps are useful tools to notice alteration in different branches of sphingolipid 
biosynthesis pathway based on microarray and other transcriptomic analysis. The high 
correlation between gene expression differences and sphingolipid alterations highlights 
the application of this tool to evaluate molecular changes associate with sphingolipid 
alterations as well as predict differences in specific metabolites that can be 
experimentally verified using sensitive approaches such as mass spectrometry. Hence, the 
combination of different bioinformatics approaches, including protein and DNA sequence 
analysis, structure modeling and pathway diagrams can provide valuable inputs for 





Appendix A – Tools for gene expression pathway analysis 
 
1)  Perl program to extract normalized glycosphingolipid gene expression values  
!/usr/bin/Perl 




my $Micro = $ARGV[0];  # Microarray file neme 
my $GeneList = $ARGV[1];  # Gene or probelist file 
 
 
open(MICRO, $Micro)||die"cannot open microarray file\n"; 
open(LIST, $GeneList)||die"cannot open genelist file\n"; 
 
 
my %hash= (); 
while(my $line = <LIST>){ 
 
 
    chomp($line); 
    my @words = split(/\t/,$line); 
    my $id = $words[0]; 




my @keys = keys(%hash); 
 
my $num = @keys; 
 
while(my $gene = <MICRO>) 
{ 
   chomp($gene); 
    for(my $i=0; $i < $num; $i++) 
    { 
  
 my $key = $keys[$i]; 
      chomp($key); 
        if ($gene =~ m/$key/i) 
   { 
     print "$gene \n"; 
         
        }    
 
     } 











Instructions for using Perl program for filtering sphingolipid genes: on windows PC install the 
Activeperl package from www.activestate.com (Perl is already installed on Mac OS in the X-terminal). 
Copy and paste the above script in text editor (notepad) and save it as ‘genefilter.pl’ in a separate folder. 
Next copy and paste the list of gene IDs and probe IDs into separate text file and save them as 
‘shingogene.txt’ or ‘sphingoprobe.txt’ in the same folder as the Perl script. Save the normalized 
microarray dataset with gene expression values and gene ID or affymetrix probe IDs in a tab delineated 
text file in the folder along with the gene/probe list and the Perl script. To filter the sphingolipid related 
gene expression values from all the microarray gene probes run the Perl script on the command line (as 
shown in the figure below for windows PC). 
‘c:\perl> perl  genefilter.pl  microarrayfile.txt sphingogene.txt > microarraysphingo.txt’   
 The script generates an output text file ‘microarraysphingo.txt’ with the selected sphingolipid gene 








2) Gene list and preselected probe IDs for Affymetrix HG-U133 plus2 
A user may use either gene list or preselected probe ids to extract gene expression information 


















































































































DEGS1    209250_at 
DEGS2    236496_at 






















3) Application of data to Pathvisio 
 
Formatting the input file 
Gene expression data for sphingolipid specific genes extracted with the perl Script (Supplement 1A) 
should be formatted into a pathvisio input file with three essential columns and saved as a comma 
separated file (.csv). An example is given below 
GeneID SystemCode Fold 
1552833_at X -1.143967291 
1552903_at X 1.010328449 
1552965_a_at X 1.422851697 
1553046_s_at X 1.220136212 
1553257_at X 1.113669687 
1553727_at X 4.407868628 
1553959_a_at X 1.83540546 
1554053_at X -2.338778491 
1554253_a_at X 1.068452133 
1554383_a_at X 1.139011527 
1554835_a_at X 2.045004684 
1555123_at X 2.645276048 
1555171_at X -1.123596112 
1555419_a_at X -2.284137975 
 
GeneID   is the gene identifier or probe ID 
SystemCode   -- type of gene identifier 
Fold – the calculated fold change for the specific gene probe.  
 
Further information about the tile format can be obtained from www.pathvisio.org 
 
Instruction of download of maps from wikipathways 
Visit www.wikipathways.org 
Browse for pathway and click for Sphingolipid metabolism 
In the download link select PathVisio (.gmpl) 






Creating Pathway diagrams with expression data in Pathvisio. 
 
Open the pathway map in Pathvisio browser 
Create a expression data using formatted expression file 
     In the menu select    Data  Import expression data 
     Select the ‘input file’ (previously prepared .csv file)  and ‘output file’ 
     Follow the steps by clicking next 
     Choose data delimiter  ‘comma’ , Next 
     Select ‘systemcode’ then Next 
 
Visualization of expression values 
     Select the dataset  Data  ‘select expression data’ 
     Select Data  ‘visualization options’ 
     Define the color criteria 
After the completion the map should be colored according to the selected criteria. 
 













Appendix B Sphingolipid Pathway maps for NCI60 cell panel
The fold change was for individual genes in cell lines were determined by taking a ratio of the gene
expression values and the average expression of the gene among all 60 cell lines.
Tumor: Cell line: Page: Tumor: Cell line: Page:
Leukemia (LE) CCRF_CEM 113 Lung (LU) A549 129
HL_60 113 EKVX 129
MOLT_4 114 HOP_62 130
RPMI_8226 114 HOP_92 130
SR 115 NCI_H226 131
K_562 115 NCI_H322M 131
NCI_H460 132
Breast (BR) MCF7 116 NCI_H522 132
MDA_MB_231 116
HS578T 117 Ovarian (OV) IGROV1 133
T47D 117 NCI_ADR_RES 133
OVCAR_3 134
Glioma (CNS) SF_268 118 OVCAR_4 134
SF_295 118 OVCAR_5 135
SF_539 119 OVCAR_8 135
SNB_19 119 SK_OV_3 136
SNB_75 120
U251 120 Prostate (PR) PC_3 136
DU_145 137
Colon (CO) COLO205 121
HCC_2998 121 Melanoma (ME) LOXIMVI 137
HCT_116 122 MALME_3M 138
HCT_15 122 M14 138
HT29 123 SK_MEL_2 139
KM12 123 SK_MEL_28 139
SW_620 124 SK_MEL_5 140
UACC_257 140
Renal (RE) 786_0 124 UACC_62 141
A498 125 MDA_MB_435 141
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